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ABBREVIATIONS 
Ad  adenovirus 
Ad3   adenovirus serotype 3 
Ad5   adenovirus serotype 5 
ADP   adenoviral death protein 
ATCC   American Type Culture Collection 
bp  basepair 
Ca  cancer 
CAR   coxsackie-adenovirus receptor 
CD   cytosine deaminase 
cGMP   current good manufacturing practices 
cox-2   cyclooxygenase-2 
CR2   constant region 2 
CRAd   conditionally replicating adenovirus 
C-terminal  carboxy-terminal 
delta2  deletion of 3 bp in E1A region 
delta24  deletion of 24 bp in CR2 of E1A  
EGF   epidermal growth factor 
EGFR  epidermal growth factor receptor 
Flt-1  vascular endothelial growth factor receptor type 1 
GM   growth medium 
GCV   ganciclovir 
6-His   six histidine amino acid residues 
HSV-TK  herpes simples virus type I thymidine kinase 
hTERT  human telomerase reverse transcriptase 
IFN   interferon 
Ig   immunoglobulin 
i.a.  intra-arterial 
i.p.   intraperitoneal 
i.t.  intratumoral 
i.v.   intravenous 
kb   kilobase 
kD   kiloDalton 
luc  firefly luciferase 
MHC I   major histocompatibility complex I 
mock control without virus 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2Htetrazolium
pfu   plaque forming unit 
Rb   retinoblastoma 
RGD(-4C)  arginine-glycine-aspartic acid (with four cysteins) 
s.c.   subcutaneous 
TK  thymidine kinase 
TSP   tumor/tissue specific promoter 
vp   viral particle 
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ABSTRACT 
Gene therapy is a promising novel approach for treating cancers resistant to or escaping 
currently available modalities. Treatment approaches are based on taking advantage of 
molecular differences between normal and tumor cells. Various strategies are currently in 
clinical development with adenoviruses as the most popular vehicle. Recent developments 
include improving targeting strategies for gene delivery to tumor cells with tumor specific 
promoters or infectivity enhancement. A rapidly developing field is as well replication 
competent agents, which allow improved tumor penetration and local amplification of the 
anti-tumor effect. Adenoviral cancer gene therapy approaches lack cross-resistance with other 
treatment options and therefore synergistic effects are possible.  
This study focused on development of adenoviral vectors suitable for treatment of various 
gynecologic cancer types, describing the development of the field from non-replicating 
adenoviral vectors to multiple-modified conditional replicating viruses. 
Transcriptional targeting of gynecologic cancer cells by the use of the promoter of vascular 
endothelial growth factor receptor type 1 (flt-1) was evaluated. Flt-1 is not expressed in the 
liver and thus an ideal promoter for transcriptional targeting of adenoviruses. Our studies 
implied that the flt-1 promoter is active in teratocarcinomas and therefore a good candidate for 
development of oncolytic adenoviruses for treatment of this often problematic disease with 
then poor outcome. 
A tropism modified conditionally replicating adenovirus (CRAd), Ad5- 24RGD, was studied 
in gynecologic cancers. Ad5- 24RGD is an adenovirus selectively replication competent in 
cells defective in the p16/Rb pathway, including many or most tumor cells. The fiber of Ad5-
24RGD contains an integrin binding arginine-glycine-aspartic acid motif (RGD-4C), 
allowing coxackie-adenovirus receptor independent infection of cancer cells. This approach is 
attractive because expression levels of CAR are highly variable and often low on primary 
gynecological cancer cells. Oncolysis could be shown for a wide variety of ovarian and 
cervical cancer cell lines as well as primary ovarian cancer cell spheroids, a novel system 
developed for in vitro analysis of CRAds on primary tumor substrates. Biodistribution was 
evaluated and preclinical safety data was obtained by demonstrating lack of replication in 
human peripheral blood mononuclear cells. The efficicacy of Ad5- 24RGD was shown in 
different orthotopic murine models including a highly aggressive intraperitoneal model of 
disseminated ovarian cancer cells, where Ad5- 24RGD resulted in complete eradication of 
intraperitoneal disease in half of the mice. 
To further improve the selectivity and specificity of CRAds, triple-targeted oncolytic 
adenoviruses were cloned, featuring the cyclo-oxygenase-2 (cox-2) promoter, E1A 
transcomplementation and serotype chimerism. Those viruses were evaluated on ovarian 
cancer cells for specificity and oncolytic potency with regard to two different cox2 versions 
and three different variants of E1A (wild type, delta24 and delta2delta24). Ad5/3cox2Ld24 
emerged as the best combination due to enhanced selectivity without potency lost in vitro or 
in an aggressive intraperitoneal orthotopic ovarian tumor model. 
In summary, the preclinical therapeutic efficacy of the CRAds tested in this study, taken 
together with promising biodistribution and safety data, suggest that these CRAds are 
interesting candidates for translation into clinical trials for gynecologic cancer. 
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REVIEW OF THE LITERATURE 
1. Introduction 
After cardiovascular disease, cancer is the second most common cause of death in Europe, 
and is currently responsible for ca. a fourth of all deaths. Whereas in younger women cervical 
cancer is among the most frequent ones, with increasing age the incidences of cancer of the 
uterine corpus or the ovaries increase and the latter becomes an important cause of mortality 
despite numerous innovations in therapy concepts (2003; Jemal, Siegel et al. 2006).  
For operable patients, surgery is the cornerstone of gynecological cancer treatment; 
confirmation of histology, adequate staging and maximal cytoreduction being the goals. Thus, 
surgical debulking or complete removal of the tumor is a requisite for a chance of curative  
treatment for nearly all types of gynecologic cancer. Some cases of cervical or endometrial 
cancer can be effectively treated with radiation or chemoradiation alone. Here, progress in 
anaesthesia, allowing surgery in patients with reduced performance levels, combined with 
improved surgical techniques, have made surgery available to more patients (Marnitz, Kohler 
et al. 2006). 
Innovations in the field of radiation with new or improved radiation sources, and three 
dimensional planning as well as advanced chemotherapy regimes with new therapeutics have 
improved the outcome of gynecologic cancer (Ozols 2006; Ozols 2006). More effective 
combination regimens (Ozols 2006; Ozols 2006) and different application routes such as 
intraperitoneal chemotherapy have been suggested to improve the outcome of advanced 
ovarian cancer (Armstrong, Bundy et al. 2006; Markman and Walker 2006; Ozols, Bookman 
et al. 2006). 
Taken together, outcomes in terms of disease-free and overall survival have improved for 
early stages, but women with metastatic disease remain often incurable (Jemal, Siegel et al. 
2006). Targeted therapies might help to overcome this obstacle, although due to an absence of 
a common driving oncogene, single targeted therapies are unlikely to yield significant benefit 
(Darcy and Schilder 2006). 
In recent decades, an intense basic research effort has begun to reveal the nature of cancer as a 
disease of genes. Specifically, epigenetic and genetic alterations of tumor suppressor and 
oncogenes are the cause of cancer. These changes can be hereditary, or – more commonly – 
arise during the lifetime of an individual. A logical result of these findings is the idea of 
correcting the molecular defects. Alternatively, these differences could be used for targeting 
an antitumor effect to malignant cells. Thus, molecularly targeted therapies stem from our 
ability to detect molecular defects that set cancer cells apart from normal tissues (Hemminki 
2002; Chon, Hu et al. 2006; Tuve, Wang et al. 2006). Cancer gene therapy includes a wide 
variety of heterogeneous approaches for which the common denominator is transfer of genes, 
which then code for the proteins or in some cases complete viruses that deliver the anti-tumor 
effect (Hauses and Schackert 2000; Vorburger and Hunt 2002; Cross and Burmester 2006). 
Gene transfer is performed by different vector systems with respective advantages and 
disadvantages. The specifics of these vector systems make them suitable for the treatment of 
either monogenic disorders, aquired diseases or for cancer. Whereas the treatment of  the 
former two typically benefits from long-term gene expression and thus a stable non-
immongenic gene transfer method, gene therapy for cancer requires effective high level 
transduction and gene expression in target cells. Currently, the most common vector systems 
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are adenoviruses (Ad), retroviruses including lentiviruses, adeno-associated viruses (AAV) 
and non-viral gene transfer systems.  
2. Vehicles for gene transfer 
A traditional vehicle is the retrovirus, which integrates into the host cell genome and can 
therefore achieve lasting gene expression. However, its major disadvantages are the 
possibility of insertion mutagenesis/oncogenesis, low transduction efficacy, difficulties in 
production of high titers and infection of only cycling cells (Luther-Wyrsch, Costello et al. 
2001; Pandya, Klimatcheva et al. 2001; Ross, Wright et al. 2001). For these reasons, 
retroviruses may be most suitable for treatment of diseases where long term gene expression 
is required. Lentiviruses may overcome some of these problems but their clinical safety or 
effifacy have not yet been demonstrated. Adeno-associated viruses are non-pathogenic single-
stranded DNA viruses which, when wild type, may integrate into the human chromosome 19 
and cause long term gene expression, whereas recombinants stay mostly episomal 
(Ponnazhagan, Curiel et al. 2001). Early preclinical studies show encouraging results 
(Vermeij, Zeinoun et al. 2001). However, recent findings suggest that adeno-associated 
viruses may cause deletions or changes in chromosome 19 (Miller, Rutledge et al. 2002). 
Finally, non-viral vectors are undergoing evaluation. Liposome vector systems are cationic 
complexes where transgenes are carried inside a lipid double-membrane, which can be 
modified to bind selectively to a specific target receptor. The liposomes enter their target cell 
via endocytosis and release subsequently the DNA-load into the cell. For treatment of cancer, 
a major problem has been low transduction efficiency, particularly prominent in vivo and 
further underlined by data obtained from clinical trials  (Lee, Yoon et al. 2000; Hortobagyi, 
Ueno et al. 2001; Rochlitz 2001; Wang, Zhang et al. 2001; Yoo, Hung et al. 2001; Chon, Hu 
et al. 2006; Cross and Burmester 2006).  
3. Cancer gene therapy approaches 
Gene therapy for cancer can be divided into at least six different categories: 1) mutation 
compensation, 2) molecular chemotherapy, 3) genetic immunopotentation, 4) genetic 
modulation of resistance/sensitivity, 5) oncolytic (conditionally replicating) viruses and 6) 
antiangiogenic gene therapy. The goal of mutation compensation is correction of a crucial  
molecular change within cancer cells. For example, mutations of tumor suppressor genes such 
as p53 or BRCA1 or overexpression of  oncogenes such as erbB-2 are major targets for 
replacement or inactivation, respectively (Nieto, Cagnoni et al. 2000; Casado, Nettelbeck et 
al. 2001) (Fig. 1). Molecular chemotherapy, also known as suicide or prodrug conversion 
gene therapy, is the selective delivery or expression of genes encoding a prodrug-activating 
enzyme for tumor cell eradication (Fig. 2). Approaches tested in the clinic include vector 
mediated delivery of herpes simplex virus thymidine kinase (HSV-TK) and Echerichia coli
cytosine deaminase (E.coli CD), which locally convert non-toxic prodrugs (e.g. ganciclovir 
for HSV-TK or 5-fluorocytosine for E.coli CD) into potent cell poisons. Lateral diffusion of 
the activated drug into untransduced neighboring cells causes additional cell killing and is 
described as the “bystander effect”. This helps alleviate the daunting task of transduction of 
each tumor cell (Elshami, Saavedra et al. 1996).  
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Fig. 1. Mutation compensation: expression of a wild type p53 gene in cells with mutated 
version of this gene causes cell death selectively in cells with former mutated gene. 
In contrast, genetic immunopotentation efforts involve the modification of either immune or 
tumor cells to augment immunological recognition of neoplastic cells (Nishida, Maeda et al. 
2002) (Fig. 3). In a phase III randomized trial in patients with renal cell carcinoma an 
autologous renal tumor cell vaccine increased the 70 month progression-free survival rates 
from 59% to 72%. The vaccination was well tolerated and only 12 adverse events out of 379 
patients were reported (Jocham, Richter et al. 2004). 
In another approach, investigators have utilized a variety of strategies to modify resistance or 
sensitivity of cells for chemotherapy or radiation in order to enhance the therapeutic index 
(Duverger, Sartorius et al. 2002; Schiedlmeier, Schilz et al. 2002).  
Oncolytic viruses, such as conditionally replicating adenoviruses (CRAds), take advantage of 
tumor specific changes, which allow preferential replication in and subsequent death of tumor 
cells.
Finally, antiangiogenic gene therapy targets the development of new vessels in tumor tissue 
thus inhibiting tumor growth.  
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Fig. 2. Suicide gene therapy: After gene delivery with a vector coding for HSVtk,
administration of ganciclovir causes death of infected cells followed by destruction of 
surrounding cells due to the bystander effect. 
Fig. 3. Immunopotentation: the patient’s own cells are extracted and infected in vitro with an 
interleukin encoding vector, followed by retransfusion of the transfected cells back into 
patient, causing an immune response to the tumor. 
4.1 Adenovirus for gene therapy 
Adenoviruses are double-stranded DNA viruses whose major capsid components are hexon, 
penton and fiber. Adenoviral infection is mediated by binding of the knob region, located at 
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the carboxy terminus of the fiber, to its corresponding receptor, which is the Coxsackie-
Adenovirus Receptor (CAR) for most serotypes. Binding is followed by interaction between 
cellular integrins and an arginine-glycine-aspartic acid motif (RGD-motif) located at the 
penton base. This binding leads to formation of endosomes and viral internalization. 
Subsequently, after this receptor-mediated endocytosis, the virus escapes from the endosome 
and the adenoviral DNA is transported in the cytoplasma microtubule- and dynein/dynactin-
dependent to the nucleus. Then the virus docks to the nuclear core complex receptor, imports 
in the nucleus and adenoviral protein synthesis, or in case of nonreplicating Ads, transgene 
expression begins (Meier and Greber 2003). Adenoviral DNA is not regularly integrated into 
the host genome, thereby resulting in a low risk of mutagenesis. Nevertheless, the limited 
duration of gene expression may render Ads less desirable for the therapy of diseases where 
long-term expression is needed, but is adequate for cancer gene therapy approaches, where the 
purpose typically is to kill the target cells. Infection is not dependent on cell cycle phase; 
therefore, both cycling and non-dividing cells are infected.  
Importantly, a most appealing feature of Ad for cancer therapy is its unparalleled capacity for 
gene transfer and expression in vivo. Further, production of high titers of cGMP Ad, 
necessary for clinical trials, is well established.  Adenoviral infection of tissues is determined 
chiefly by the degree of CAR expression (Zabner, Freimuth et al. 1997; Miller, Buchsbaum et 
al. 1998; Kaner, Worgall et al. 1999; Li, Pong et al. 1999; Walters, Grunst et al. 1999; 
Fechner, Wang et al. 2000; Okegawa, Li et al. 2000; Wan, Leon et al. 2000; Cohen, Shieh et 
al. 2001; Cripe, Dunphy et al. 2001; Nalbantoglu, Larochelle et al. 2001; Okegawa, Pong et 
al. 2001; Seidman, Hogan et al. 2001; Shayakhmetov, Li et al. 2002). The natural tropism of 
intravascular Ad results in accumulation mainly in the liver, spleen, heart, lung and kidneys 
(Huard, Lochmuller et al. 1995; van der Eb, Cramer et al. 1998; Reynolds, Dmitriev et al. 
1999; Wood, Perrotte et al. 1999; Bilbao, Gerolami et al. 2000). Tissue macrophages, such as 
Kuppfer cells of the liver, have a major role in clearing Ad from blood REFs. Although CAR 
is expressed ubiquitously on most normal epithelial tissues, lack or down-regulation of CAR 
has been reported for various tumor types and may be associated with tumor aggressiveness 
and could be an ubiquitous phenomenon (Dmitriev, Krasnykh et al. 1998; Hemmi, Geertsen et 
al. 1998; Miller, Buchsbaum et al. 1998; Kasono, Blackwell et al. 1999; Khuu, Conner et al. 
1999; Li, Pong et al. 1999; Vanderkwaak, Wang et al. 1999; Dodson, DeMarzo et al. 2000; 
Fechner, Wang et al. 2000; Heinicke, Hemmi et al. 2000; Kelly, Miller et al. 2000; Okegawa, 
Li et al. 2000; Anders, Ding et al. 2001; Cripe, Dunphy et al. 2001; Douglas, Kim et al. 2001; 
Okegawa, Pong et al. 2001; Seidman, Hogan et al. 2001; Hemminki and Alvarez 2002; 
Shayakhmetov, Li et al. 2002). Also, recent preliminary findings suggest a connection 
between CAR function and cell adhesion, perhaps associated with a tumor suppressing effect 
(Okegawa, Li et al. 2000; Okegawa, Pong et al. 2001), as CAR may be a transmembrane 
component of tight junctions (Cohen, Shieh et al. 2001). Furthermore, it has been suggested 
that CAR expression correlates inversely with the tumor stage (Okegawa, Li et al. 2000; 
Anders M. 2001), and that an over-activity of the RAS-MAPK pathway, found in many or 
most tumors, may cause downregulation of CAR (Anders M. 2001).  
Due to the broad tropism of adenoviruses, targeting to tumors could be useful. Two principal 
means for achieving this goal exist: a) transcriptional targeting and b) transductional targeting. 
Transcriptional targeting involves genetically limiting the expression of the introduced gene 
to specific tissues through the use of the promoter sequences of genes upregulated in these 
tissues (Miller and Whelan 1997 . These regulatory sequences are referred to as tissue-specific 
promoters (TSPs) {Binley, 1999 #283; Vile, Sunassee et al. 1998; Vassaux 1999). Introduced 
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genes, under the control of a TSP, are preferentially expressed in tissues that activate the TSP 
(Hart 1996). 
Transductional targeting involves the chemical or genetic modification of adenoviruses, 
redirecting its tropism from the native receptor, to a new one preferentially expressed on 
target cells. An ideal retargeting strategy would involve blocking binding to CAR while 
introducing a new tropism to a tumor associated receptor or cell-surface marker. Recent 
advances in the understanding of adenovirus structure and biology have led to many 
significant achievements in these areas (Russell 2000; Volpers and Kochanek 2004). This lead 
to incorporation of various peptide ligands into different locations of the fiber, hexon or 
penton base, as well as precice point mutations in the fiber knob domains (Volpers and 
Kochanek 2004). 
4.2 Cancer trials with adenoviral vectors 
Adenoviruses are currently the most common vector system for clinical gene therapy trials for 
cancer. By the end of the year 2005, more than 380 clinical trials were approved and over 200 
still recruiting (Database 2006). Most were phase I or phase II, which means their primary 
goal is determining the safety of the agents (phase I) or their potential efficacy (phase II). 
Genetic immunotherapy has been the most commonly tested clinical approach. Adenoviruses 
may be ideal vaccination vectors (Schreiber, Kampgen et al. 1999; Tillman, de Gruijl et al. 
1999; Mincheff, Tchakarov et al. 2000; Stephenson 2001; Shiver, Fu et al. 2002), since they 
are strongly immunogenic and combine both safety and efficacy.  
In addition to genetic immunotherapy, cancer trials involving adenoviral vectors can be 
divided in three main groups: a) suicide gene therapy, b) gene replacement, and c) receptor 
targeting. Suicide gene therapy typically features introduction of a prodrug-converting 
enzyme. Phase I trials have been performed for the treatment of glioma (Eck, Alavi et al. 
1996; Sandmair, Loimas et al. 2000; Trask, Trask et al. 2000), ovarian cancer (Alvarez and 
Curiel 1997; Alvarez, Gomez-Navarro et al. 2000; Hasenburg, Tong et al. 2000), prostate 
cancer (Herman, Adler et al. 1999; Koeneman, Kao et al. 2000) and mesothelioma (Sterman, 
Treat et al. 1998). Interestingly, when glioma patients were resected and randomized into Ad-
HSVtk/ganciclovir, retrovirus-HSVtk/ganciclovir or control groups, overall survival was 
significantly improved in the Ad-HSVtk/ganciclovir group (Sandmair, Loimas et al. 2000). 
Another randomized study with 36 glioma patients resulted as well in a significant increase 
for survival in patients treated with local AdvHSV-tk injections followed by systemical 
ganciclovir compaired to controls (Immonen, Vapalahti et al. 2004). A phase III study here is 
in progress. 
Several trials combine suicide gene therapy with more common treatment options. Ten 
patients with recurrent ovarian cancer underwent secondary debulking followed first by 
intraperitoneal suicide gene therapy with an Ad coding for HSVtk and then intravenous 
ganciclovir administration and topotecan chemotherapy. When the study was published, three 
out of ten patients were still alive with a follow-up between 30 and 31 months (Hasenburg, 
Tong et al. 2001). In another phase I/II study, adenoviral suicide gene therapy with or without 
hormonal treatment was combined with radiotherapy for prostate cancer. The aim of this 
study was the expansion of the therapeutic index of radiotherapy (Teh, Aguilar-Cordova et al. 
2001). No additional toxicity was noted from the combination and safety of the approach 
could be demonstrated. Two years after treatment, no significant long-term toxicity was 
detected. In the group with low-risk patients, negative biopsies and lack of  metastases was 
seen at 21 months (Aguilar LK 2002).  
With regard to gene replacement strategies, p53 has been a major target in phase I and II trials 
(Roth 1996; Roth, Swisher et al. 1998; Schuler, Rochlitz et al. 1998; Kauczor, Schuler et al. 
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1999; Swisher, Roth et al. 1999; Atencio, Warren et al. 2001; Buller, Shahin et al. 2001; Hao, 
Rowinsky et al. 2001; Muller, Coleman et al. 2001; Pagliaro, Keyhani et al. 2001; Pisters, 
McDonnell et al. 2001). Perhaps the most encouraging results were seen when Ad was given 
intratumorally in combination with chemotherapy (Schuler, Herrmann et al. 2001). The 
Chinese gouvernment approved in 2003 a recombinant Ad-p53 (“Gendicine”) for clinical use 
(Patil, Rhodes et al. 2005; Peng 2005). 
Another tumor suppressor gene used in a phase I study is mda-7. Ten patients with solid 
tumors were injected intratumorally followed by excision of the lesions, which allowed 
demonstration of transgene expression (Cunningham C 2002). Receptor targeting has been 
endeavored mainly for ovarian cancer with erbB2 as the target (Alvarez and Curiel 1997; 
Alvarez, Barnes et al. 2000). None of these studies showed dose-limiting side-effects, even 
with a viral dose of 7.5x1013 VP daily for five days (Buller, Shahin et al. 2001). Therefore, it 
can be concluded that cancer gene therapy with replication deficient adenoviral vectors is safe 
and although evidence of gene transfer in general has been variable, in some cases there is 
evidence of efficacy.  
5.1 Transcriptional targeting 
A promoter is the component of the genetic transcriptional unit that is involved in binding of 
the RNA polymerase, required for initiation of mRNA transcription. Further, the promoter is 
activated by transcription factors presented under tissue-specific control. Therefore, in order 
for a promoter to be activated in a particular tissue type, that tissue must express specific 
factors that recognize the promoter. A number of TSPs have been studied for cancer gene 
therapy, but some promoters lack sufficient activity, specificity, or both. Therefore, recent 
research has focused on rigorously evaluating candidate promoters with regard to these 
attributes for transcriptional targeting of viruses (Fig. 4A).   
5.1.1 Tumor-specific promoters 
One of the earliest tumor-specific promoters explored for cancer was the carcinoembryonic 
antigen (CEA) promoter, expressed in most gastric, pancreatic, and lung cancers (Tanaka, 
Kanai et al. 1996). This promoter was used to drive HSVtk expression and CEA-negative cell 
lines were resistant to ganciclovir therapy while CEA-positive cells were 1000 times more 
sensitive (Osaki, Tanio et al. 1994). Upon intraperitoneal injection into mice bearing CEA-
expressing tumors, significant regression could be noted (Osaki, Tanio et al. 1994). 
Importantly, a significant by-stander effect was reported (Tanaka, Kanai et al. 1996; Tanaka, 
Kanai et al. 1997). An Ad carrying either lacZ or CD under the CEA promoter showed 
specific expression in tumor xenografts and was able to increase survival time (Lan, Kanai et 
al. 1997). Also, intravascular administration of an Ad employing the CEA promoter showed 
little toxicity in the normal liver  (Brand, Loser et al. 1998). For possible treatment of 
hepatomas, the promoter of the alpha-fetoprotein (AFP) has been investigated. When an Ad 
employing this promoter was injected subcutaneously into hepatomas in vivo, tumor 
regression was noted (Kanai, Lan et al. 1997).
For treating gynecological cancers, a number of promoters have been explored. The L-plastin 
promoter (LP-P) was used to transcriptionally control the expression of lacZ in ovarian and 
breast cancer cell lines, and was compared to the ubiquitously expressed cytomegalovirus 
(CMV) promoter (Chung, Schwartz et al. 1999). Expression was observed in tumor cell lines 
and ascites samples with both promoters, but little activity was seen in normal human skin 
fibroblasts and normal peritoneum with the LP-P. Another report on LP-P showed specific 
expression of lacZ and CD in ovarian and bladder cancer cell lines when compared to the 
CMV promoter (Peng, Won et al. 2001). Over three-quarters of human epithelial ovarian 
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carcinomas express the DF3 protein, while normal peritoneal mesothelium does not 
(Friedman, Hayes et al. 1986). The DF3 promoter showed ovarian cancer-specific activity 
when driving the expression of BAX in vitro (Tai, Strobel et al. 1999). Upon intraperitoneal 
injection into ovarian tumor bearing nude mice, BAX expression was most prominent in tumor 
tissue and greater than 99% eradication of tumor explants was reported. 
The cyclooxygenase-2 (Cox-2) promoter has also been investigated in ovarian tumor cell 
lines, along with the midkine (MK) promoter. Both promoters were activated in a panel of 
ovarian cancer cell lines, as well as, ovarian primary tumor cells, with a reduced level of 
activity in normal primary mesothelium and liver (Casado, Gomez-Navarro et al. 2001).    
The Cox-2 promoter has also been explored in the context of gastric carcinomas. The activity 
profile of the promoter correlated to the Cox-2 RNA status of gastric carcinoma cell lines, and 
upon intravascular injection, liver expression with the Cox-2 promoter was lower than with 
the CMV promoter. The promoter was sufficiently active to cause tumor cell killing when 
driving HSVtk in Cox-2 positive cell lines but not negative lines. In vivo administration 
resulted in less liver toxicity with the Cox-2 promoter versus the CMV promoter (Yamamoto, 
Alemany et al. 2001).  
The secretory leukoprotease inhibitor (SLPI) gene is expressed in several different 
carcinomas, including ovarian cancer. Its expression in normal organs, such as the liver, is 
low (Abe, Tominaga et al. 1997). Therefore, the SLPI promoter was utilized to drive 
transgene expression in ovarian cancer cell lines and primary tumor cells isolated from patient 
samples (Barker S.D. 2002). The promoter was activated in both cell lines and primary tumor 
cells in an Ad context in vitro. A murine orthotopic model of peritoneally disseminated 
ovarian cancer was used to demonstrate high tumor gene expression versus low liver 
expression with the SLPI promoter, and that Ad-delivered HSVtk under the control of the 
SLPI promoter is able to increase survival in combination with ganciclovir (Barker S.D. 
2002).Further TSPs that have been studied with promising preclinical results include 
tyrosinase, ERBB2, surfactant protein B, proopiomelanocortin and flt-1 (Ring, Harris et al. 
1996; Siders, Halloran et al. 1996; Strayer, Guttentag et al. 1998; Lee, Martinson et al. 2001).   
5.1.2 Tumor vasculature-specific promoters
Targeting the endothelium of tumors may be amenable to gene therapy. This tissue is 
commonly independent of tumor type and more easily accessible to intravascular vector 
administration. Also, endothelial cells (EC) are not malignant and thus are less sensitive to 
selection pressure and rarely gain resistance to treatment (Nettelbeck, Jerome et al. 2000). E-
selectin expression is minimal in normal blood vessels but high in the capillaries of tumors 
and the promoter was used for driving gene expression in an Ad. Upon infection, EC cell lines 
expressed high levels of reporter gene expression, while non-EC cell lines showed low 
expression. The addition of TNF-alpha, an inducer of the promoter, further increased the E-
selectin’s activity (Walton, Wang et al. 1998). The murine preproendothelin-1 (PPE-1) 
promoter was also used as a TSP for adenoviral-mediated delivery to EC cells. Systemic 
administration to lung tumor-bearing mice resulted in gene expression in the new vasculature 
of primary tumors (Varda-Bloom, Shaish et al. 2001). 
5.1.3 Treatment responsive promoters 
Another strategy for cancer gene therapy involves restricting gene expression with a 
conventional form of treatment, such as chemotherapy or radiation.  For example, the early 
growth response gene 1 (EGR-1) promoter, which is radiation inducible, has been used as a 
TSP for the specific expression of lacZ and HSVtk in glioma and hepatocellular carcinoma 
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cells. Radiation-induced transcription of EGR-1 in these cells was accomplished with 
relatively low doses (Manome, Kunieda et al. 1998; Katabi, Chan et al. 1999). 
A combination of radiation with a radiation induced adenoviral gene therapy is under 
development for cervical cancer models and resulted in first promossing results (Rein 2005). 
TSPs have the potential to decrease the toxicity of cancer gene therapy and represent a 
powerful tool for the specific targeting of transgene expression to neoplastic cells.  However, 
they do not increase the efficacy of Ad infection. By combining transcriptional targeting with 
infectivity enhancement, improved vectors can be developed.
5.2 Transductional targeting 
Transductional targeting strategies (Fig. 4B) have the potential to increase gene transfer to 
target tissues and reduce sequestration by non-target tissues.  There are two primary means of 
transductional targeting: a) genetic and b) physical. These are sometimes referred to as one-
component and two-component targeting, respectively. The former involves the genetic 
modification of adenoviruses to incorporate ligands, which recognize specific cellular 
receptors, and/or block native receptor binding.  
5.2.1 Genetic transductional targeting 
Several areas exist in adenoviruses that are amenable for genetic insertion of ligands.  One of 
these is the HI loop of the fiber, which was used as an insertion site for an integrin binding 
RGD-4C motif (Dmitriev, Krasnykh et al. 1998; Krasnykh, Dmitriev et al. 1998). 
RGDTKSSTR is an RGD-4C modified adenoviral vector containing HSVtk for molecular 
chemotherapy and the human somatostatin receptor subtype-2 (SSTR2) gene for non-invasive 
imaging (Hemminki, Belousova et al. 2001). The RGD-4C modification allowed enhanced 
infectivity of ovarian cancer cell lines and primary ovarian tumor cells. This enhancement was 
also observed in the presence of malignant ascites. Further, clinical treatment was mimicked 
by administering RGDTKSSTR intraperitoneally, in the presence of malignant ascites from 
ovarian cancer patients, to mice with disseminated ovarian cancer. A significant survival 
advantage was seen in comparison to an isogenic non-RGD-4C virus and other controls. 
Importantly, the virus could be non-invasively imaged in vivo for more that two weeks 
(Hemminki, Zinn et al. 2002). This approach was undergoing clinical evaluation with ovarian 
cancer patients with peritoneally disseminated disease (2001). Results of this study are not 
published so far. 
In another study, an adenovirus containing luciferase and the RGD-4C modification was 
analyzed in comparison to a virus without the modification (Kanerva, Wang et al. 2002). In 
stringent preclinical substrates, including primary ovarian tumor cells (in the absence and 
presence of neutralizing antibodies) and in a murine model of ovarian cancer, increased gene 
expression was observed with the RGD-modified virus. 
Because adenovirus has a propensity to localize to the liver, with potential for hepatotoxicity, 
untargeting the liver is an important goal (Lieber, He et al. 1997; Hemminki and Alvarez 
2002). In this regard, viruses were created, which lack binding to CAR and to cellular 
integrins since both play a significant role in liver uptake. These viruses could be shown to be 
effectively reduced in their liver transduction capability (Einfeld, Schroeder et al. 2001). By 
additional ablation of the heparin sulfate glycosaminoglycan-binding site of the fiber shaft, 
which is proven to be a keypart of adenoviral-5 infection besides CAR and integrins, liver 
transduction in vitro and in vivo could be abrogated, while transduction of target tissue was 
reduced as well but to a much smaller degree (Bayo-Puxan, Cascallo et al. 2006). 
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5.2.2 Fiber chimerism 
Not all adenoviral serotypes bind CAR and therefore have a different tropism. Fiber 
chimerism involves replacing the fiber or knob domain with a knob of a different serotype 
(Krasnykh, Mikheeva et al. 1996; Von Seggern, Huang et al. 2000; Kanerva, Zinn et al. 2003; 
Raki, Kanerva et al. 2005).  For example, the Ad3 serotype has a yet unidentified receptor. 
Whereas first CD46 was reported to be the Ad3 receptor (Sirena, Lilienfeld et al. 2004), 
recent publications suggest that CD46 is a receptor for the B-group Ads but not for Ad3 
(Marttila, Persson et al. 2005; Tuve, Wang et al. 2006). 
Nevertheless, a chimeric Ad5/3 vector increased gene transfer by up to 291-fold in ovarian 
cancer cell lines and primary tumor cells (Kanerva, Mikheeva et al. 2002). Importantly, the 
biodistribution and murine toxicity of the chimeric and RGD modified viruses was not 
significantly different from the Ad5 based vectors, which have proven safe in clinical trials. 
Further, adenoviruses with polylysine motifs in the fiber C-terminus, enabling CAR-
independent binding to heparan sulfate proteoglycans (HSPG) have been constructed. 
Heparan sulfate proteoglycans represent a subgroup of adenovirus receptors, especially 
expressed on tumor cells. Therefore, these viruses have showed increased infectivity for 
tumor cells (Kangasniemi, Kiviluoto et al. 2006; Ranki, Kanerva et al. 2006; Sarkioja, 
Kanerva et al. 2006). 
5.2.3 Physical transductional targeting 
Physical targeting involves complexing adenovirus with a bispecific molecule, which both 
blocks binding to CAR and redirects the virus to new specific receptors.  A major advantage 
to using this form of targeting is the abundance of antibodies and ligands that can be utilized. 
For example, basic fibroblast growth factor (FGF2) has been conjugated to the Fab fragment 
of an anti-knob antibody. This Fab-FGF2 conjugate was able to increase transgene expression 
by more than 9-fold in ovarian cancer cell lines, and upon intraperitoneal injection of HSVtk 
viruses into tumor-bearing mice, survival was prolonged from 36 to 44 days (Rancourt, 
Rogers et al. 1998). In addition decreased hepatic toxicity was demonstrated (Gu, Gonzalez et 
al. 1999). This strategy resulted in increased survival also in a melanoma xenograft mouse 
model (Gu, Gonzalez et al. 1999). Other Fab-ligand conjugates have been employed in a 
similar manner with promising results (Douglas, Rogers et al. 1996; Goldman, Rogers et al. 
1997; Haisma, Pinedo et al. 1999; Reynolds, Zinn et al. 2000).  
Another transductional targeting concept is the sCAR-ligand conjugat, utilizing the secretory 
ectodomain of CAR fused with a targeting ligand. For example, epidermal growth factor 
(EGF) has been conjugated to sCAR and used to target adenoviruses to cancer cells that 
overexpress the EGF receptor (Dmitriev, Kashentseva et al. 2000; Wesseling, Bosma et al. 
2001). A dose-dependent increase of luciferase expression was reported in cell lines with both 
a replication-defective and a oncolytic adenovirus (Hemminki, Dmitriev et al. 2001). When 
infected cells were injected subcutaneously, only 1% of targeted adenoviral-infected cells 
were needed to inhibit tumor growth and only 5% were needed to heal tumors. sCAR has also 
been fused to a single-chain antibody specific for the c-erbB-2 oncoprotein. Again, significant 
increases in gene transfer were observed (Kashentseva, Seki et al. 2002). 
Although two-component targeting has shown promising results for retargeting adenovirus to 
new receptors, it may present some disadvantages. Two-component gene delivery systems 
have more complex pharmacodynamics and -kinetics, and their stability in humans has not yet 
been studied. Therefore, one-component systems may be more easily applicable to human 
cancer gene therapy trials. 
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Fig. 4. A) Transcriptional targeting: a tissue specific promoter is placed in front of the 
transgene or a gene essential for viral replication. Only cells expressing the tissue specific 
promoter can activate transcription of transgene (non-replicative adenoviruses) or viral 
replication (replicative adenoviruses). B) Transductional targeting: The fiber knob of the 
adenovirus, responsible for determining the tropism, is replaced or blocked with a retargeting 
moiety. This redirects the virus to a cancer associated receptor. 
6.1 Conditionally replicating adenoviruses (CRAds) as oncolytic agents 
Although non-replicating first generation adenoviruses have provided high in vitro and in vivo
transduction rates and good safety data, clinical trials have suggested, that the antitumor effect 
may not be sufficient in a single treatment approach (Glasgow, Bauerschmitz et al. 2004). 
Although tumor targeting and infectivity enhancement have improved preclinical results 
dramatically, it is possible that  clinical application of non-replicating agents may require 
multiple rounds of re-administration. Viruses that replicate and spread specifically inside the 
tumor have been suggested as a way to improve tumor penetration with an additional benefit 
of local amplification of effect. To this end, CRAds have been developed. These viruses are 
genetically modified to take advantage of tumor specific changes that allow preferential 
replication of the virus in target cells (Alemany, Balague et al. 2000; Curiel 2000; Curiel 
2000; Gomez-Navarro and Curiel 2000; Heise, Hermiston et al. 2000; Balague, Noya et al. 
2001). The viral replication cycle causes oncolysis of the cell, resulting in the release of the 
newly generated virions and subsequent infection of neighboring cells (Fig. 5). Thus, the anti-
tumor effect is not delivered with a transgene but by the actual replication of the virus. In 
theory, the oncolytic process continues as long as target cells for the virus persist.
There are two main ways to control viral replication. One is the control of replication 
regulators, such as the viral early gene E1, with TSPs, resulting in Type I CRAds. The other 
method involves introduction of deletions in the viral genome (Type II CRAd) that require 
specific cellular factors to compensate the effects of these deletions (Heise, Sampson-
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Johannes et al. 1997; Fueyo, Gomez-Manzano et al. 2000). Further, both approaches can be 
combined with the potential for increased specificity (Nettelbeck, Rivera et al. 2002). 
A promoter is a DNA sequence that enables a gene to be transcribed and can work in concert 
with other regulatory regions (e.g. enhancers, silencers, insulators) to direct the level of 
transcription of a given gene. In case of CRAds, the transcription level of genes critical for the 
replication process is controlled, allowing replication of the virus only in those cells, where 
the promoter element is active.  
Various promoters have been used to control viral replication (Rodriguez, Schuur et al. 1997; 
Hallenbeck, Chang et al. 1999; Yu, Sakamoto et al. 1999; Hernandez-Alcoceba, Pihalja et al. 
2000; Kurihara, Brough et al. 2000; Bauerschmitz, Guse et al. 2006; Takayama, Reynolds et 
al. 2006; Zhu, Chen et al. 2006). Typically, the TSP is placed to control expression of E1A, 
the crucial regulator of Ad replication. PSA and kallikrein-2 have been used in the context of 
prostate cancer and AFP has been used for hepatoma (Rodriguez, Schuur et al. 1997; Gu, 
Gonzalez et al. 1999; Hallenbeck, Chang et al. 1999). When the DF3/MUC1 promoter was 
used to drive expression of E1A in breast cancer cells, replication at levels comparable to 
wild-type Ad was seen, while in negative cell lines, replication was decreased. A single 
intratumoral injection of this TSP-controlled CRAd resulted in significant reduction of tumor 
burden (Kurihara, Brough et al. 2000). For the treatment of pediatric solid tumors, a CRAd 
featuring the midkine (MK) promoter was utilized. This CRAd achieved specific and high 
levels of replication in MK-positive cell lines and was able to induce tumor cell killing in 
vitro (Adachi, Reynolds et al. 2001). To further increase the oncolytic effect, transgenes for 
cytokines or prodrug-activating enzymes have been included (Freytag, Rogulski et al. 1998; 
Wildner, Morris et al. 1999; Kurihara, Brough et al. 2000). The latter approach could also 
allow abrogation of virus replication in case of toxicity. 
Heretofore, three to four approaches have been utilized for creation of deletion type CRAds. 
Here, the replication of the virus is limited by insertion of a deletion in a viral replication 
gene, which blocks replication in normal cells, but can be overcome by mutated cells, 
allowing replication exclusively in those cells.  
The first one was ONYX-015, which has two mutations in the gene coding for the E1B 55-kd 
protein (Cohen and Rudin 2001; McCormick 2003). The purpose of this protein is binding 
and inactivation of p53 in infected cells, for induction of S-phase, required for virus 
replication (Bischoff, Kirn et al. 1996; Heise, Sampson-Johannes et al. 1997; Heise, Williams 
et al. 1999; Rogulski, Freytag et al. 2000). Thus, this virus might have preference for 
replication in cells with mutated p53, a common feature in human tumors (Bischoff, Kirn et 
al. 1996), although alternative mechanisms have also been suggested (Macrae, Neve et al. 
2005), and selectivity in general has been disputed (Edwards, Dix et al. 2002; Wadler, Yu et 
al. 2003). Nevertheless, initial studies have suggested that this agent replicates more 
effectively in tumor than in normal cells (Heise, Sampson-Johannes et al. 1997; Rothmann, 
Hengstermann et al. 1998; Hay, Shapiro et al. 1999; Alemany, Balague et al. 2000; Dix, 
Edwards et al. 2001). Unfortunately, the function of E1B55kD is not limited to p53 binding 
(Dix, Edwards et al. 2001), which causes inefficient replication of the virus compared with the 
wild type adenovirus (Barker and Berk 1987; Bischoff, Kirn et al. 1996; Hay, Shapiro et al. 
1999). In addition, recent studies have suggested replication of ONYX-015 in nontarget 
normal tissue (Wadler S 2002; Cherubini, Petouchoff et al. 2006).  
The second group of deletion mutants have a 24 bp deletion in the constant region 2 (CR2) of 
the E1A gene (Heise, Sampson-Johannes et al. 1997; Fueyo, Gomez-Manzano et al. 2000; 
Suzuki, Fueyo et al. 2001). This domain of the E1A protein is responsible for binding the 
retinoblastoma tumor suppressor/cell cycle regulator protein (Rb), required for effective 
replication (Russell 2000). Viruses with this type of deletion have reduced ability to overcome 
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the G1-S checkpoint and replicate efficiently only in cells where this interaction is not 
necessary, e.g. tumor cells defective in the Rb-p16 pathway (Fueyo, Gomez-Manzano et al. 
2000; Heise, Hermiston et al. 2000). Appropriately, this pathway seems to be inactive in 
almost all human tumors (Sherr 1996). It has been shown that replication of CR2-deleted 
viruses is attenuated in non-proliferating normal cells (Fueyo, Gomez-Manzano et al. 2000; 
Heise, Hermiston et al. 2000). Interestingly, abrogation of replication was also demonstrated 
when Rb was re-introduced into otherwise permissive cells (Fueyo, Gomez-Manzano et al. 
2000).
Adenoviruses with mutations in CR1 and CR2 domains of E1A were found to replicate 
selectively in tumor cells expressing human papillomavirus E6 and E7 oncoproteins (Balague, 
Noya et al. 2001). Further, CRADs featuring  an additional mutation in CR3, the binding site 
for p300, cell cycle regulator, have been described (Doronin, Toth et al. 2000). These viruses 
were further modified by replacing the natural promoter of E4 by a TSP (Doronin, 
Kuppuswamy et al. 2001).  
Fig. 5. Conditionally replicating adenoviruses are restricted in their replication to specific 
factors of their target (cancer) cells. Replication results in oncolytic death and release of 
virions to surrounding cells.  
6.2 Targeted conditionally replicating adenoviruses 
Non-targeted CRAds infect cells mostly based on their CAR-level, which may be highly 
variable in clinical cancers. Nevertheless, even such first generation CRAds have shown 
evidence of clinical utility (Hemminki and Alvarez 2002). These initial successes suggest that 
if efficiency of infection and specificity of replication of the agents could be enhanced, further 
improvements in clinical efficacy could be gained. This is corroborated by demonstration of 
the close association between infectivity and oncolytic potency (Shinoura, Yoshida et al. 
1999; Douglas, Kim et al. 2001; Hemminki, Dmitriev et al. 2001). Consequently, infectivity 
enhanced CRAds have been constructed, with impressive preclinical efficacy. Ad5- 24RGD 
features an RGD-4C modification of the fiber (Suzuki, Fueyo et al. 2001; Lamfers, Grill et al. 
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2002), and displays similar oncolytic potency to wild type virus in ovarian cancer cells. 
Further, this virus is able to replicate in ovarian cancer primary cell spheroids and results in 
significantly prolonged survival in an aggressive orthotopic ovarian cancer model 
(Bauerschmitz, Lam et al. 2002). These developments have led to clinical trial protocols, 
where glioma and ovarian cancer patients will be treated with the Ad5- 24RGD virus 
(Kanerva and Hemminki 2005). 
As another approach, fiber-chimerism was used to increase infectivity of CRAds for tumor 
cells. These viruses contain chimeric fibers with the tail and shaft from Ad5 and the knob 
domain of Ad3 (Kanerva, Mikheeva et al. 2002; Kanerva, Wang et al. 2002; Kanerva, Zinn et 
al. 2003; Breidenbach, Rein et al. 2004) and Ad5/3 24 showed increased oncolytic potency 
and preferential replication within tumor tissue. Here as well a protocol for a clinical trial is 
approved and this trial is supposed to open shortly. Besides the 5/3 chimera, chimeras Ad5/11 
(Stecher, Shayakhmetov et al. 2001; Yu, Takenobu et al. 2005) and Ad5/35 (DiPaolo, Ni et al. 
2006; Ni S 2006) are investigated (Stone and Lieber 2006). 
Recent publications use double or even triple targeted CRAds to increase specificity while 
oncolytic potency is maintained (Nettelbeck, Rivera et al. 2002; Kanerva, Bauerschmitz et al. 
2004; Bauerschmitz, Guse et al. 2006). For example, the combination of a tumor specific 
promoter cox2L, E1A transcomplementation and 5/3-fiber chimerism resulted in the CRAd 
Ad5/3cox2Ld24, showing highly selective replication in tumor tissue without reducing 
potency (Bauerschmitz, Guse et al. 2006). 
A major problem in assessing CRAd efficacy and safety preclinically, is the lack of an 
appropriate animal model. Human serotype Ads or CRAds do not replicate productively in 
commonly used mouse or other animal models. Therefore, meaningful safety data is difficult 
to obtain, and efficacy data may be skewed due to deficient immune responses in xenograft 
models. To this end, several new models were investigated up to now, and cotton rats (Toth, 
Spencer et al. 2005), Syrian hamsters (Thomas, Spencer et al. 2006) or swine (Jogler, 
Hoffmann et al. 2006) showed at least to a certain degree replication of human Ads.  
6.3 Cancer trials with CRAds 
The first cancer trials with replicating adenoviruses were done shortly after the virus was 
detected in the 1950s. Various serotypes of wild type adenoviruses were applied 
intratumorally, intravenously & intraarterially in combination or intravenously into patients 
with cervical carcinoma. The effect of immune suppression was also investigated. The overall 
response rate, measured as formation of necrotic areas, was 65% (Smith, Huebner et al. 1956). 
The authors do not describe severe side effects, but relapse was common. The first trial with a 
CRAds started nearly 50 years later and was predicated on the development of viral agents 
where replication was more selective for the target tissue (Table I). 
The first CRAd used in clinical trials was the ONYX-015 virus. In a limited number of biopsy 
specimens, replication of the agent in tumor cells was demonstrated and the safety data was 
excellent (Ganly, Eckhardt et al. 2000; Nemunaitis, Ganly et al. 2000). Since oncolysis can be 
synergistic to the effects of radiation or chemotherapy and side effects are theoretically non-
overlapping (Heise, Sampson-Johannes et al. 1997; Rogulski, Freytag et al. 2000), it seems 
obvious to combine CRAd approaches with these treatments. Recent clinical studies show 
promising results and impressive safety data (Khuri, Nemunaitis et al. 2000; Lamont, 
Nemunaitis et al. 2000; Nemunaitis, Ganly et al. 2000).  
Exciting data was obtained in a phase II study utilizing a combination of intratumorally 
injected ONYX-015 with simultaneous cisplatin and 5-fluorouracil chemotherapy in 30 
patients with advanced stage head and neck cancer (Khuri, Nemunaitis et al. 2000). Eighty-
three percent of the tumors responded; in 63% the response was objective with more than 
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50% tumor size reduction. Partial response was shown in 36%, and 27% showed a complete 
response. This is of interest since head and neck cancer is often refractory to available 
treatments. Though patients had several tumors, only one was chosen for viral injection. In 
follow-up, the non-injected tumors relapsed more frequently than the injected tumors. Similar 
data was obtained in another study with a similar approach (Lamont, Nemunaitis et al. 2000). 
A phase III trial with ONYX-015 was attempted in the US in 2002 (Lamont, Nemunaitis et al. 
2000), but it appears that production issues prevented initiation of this trial. Instead, a phase 
III trial was performed in China with a closely related virus, H101 (Xia, Chang et al. 2004). 
Adding virus to chemotherapy increased response rates from 39.6 to 78.8 %, while evidently 
no increase in severe toxicity was seen. This is the only randomized trial with oncolytic 
viruses performed thus far..
Another CRAd used in clinical studies is CV-706, where viral replication is under the control 
of the PSA promoter (DeWeese, Drew et al. 2001). In a phase I study with 20 patients, good 
safety data could be obtained. In addition, preliminary evidence of viral replication and 
antitumor effect could be observed. 
7. Model systems – primary cells and spheroids 
The preclinical development of novel approaches with replication competent viruses is limited 
by assay substrates. As a result of adaptation to growth in vitro, established cell lines may 
have undergone geno- and phenotypic changes, resulting in a disconnect between data 
obtained from cell lines and clinical specimens. The translational approach from the bench to 
the clinic would benefit from models that reproduce the patient phenotype as closely as 
possible.  In this regard, the isolation of pure cancer cells from patient samples is an attractive 
concept. A method for the isolation of primary ovarian tumor cells from the ascitic fluid of 
patients diagnosed with ovarian adenocarcinoma has been described.  Populations of up to 
96% purity have been isolated in this manner (Barker, Casado et al. 2001). Unfortunately, 
primary tumor cells are difficult to analyze ex vivo for virus replication due to their limited 
viability in culture (Casado 2001), which is approximately seven days and too short for 
typical assays. In addition, monolayers may not reflect virus dissemination characteristics 
appropriately as most human solid tumors are three dimensional. Therefore, model systems 
based on three-dimensional aggregates or spheroids of unpassaged and purified ovarian 
cancer cells have been developed to overcome these obstacles (Lam, Kanerva et al. 2001; 
Kanerva, Zinn et al. 2003; van Beusechem, Mastenbroek et al. 2003; Rein, Breidenbach et al. 
2005). Spheroids were viable for more than four weeks and allowed quantitation of CRAd 
replication.
8. Future prospects 
With increasing understanding of the molecular reasons for cancer, gene therapy has emerged 
as a logical potential therapeutic option. Following initial optimism and subsequent 
disappointment, rigorous preclinical and basic research is now beginning to result in clinically 
feasible approaches. Considering the immunogenicity of adenoviruses, while useful for 
mounting an immune response to the tumor, has the potential for severe or even fatal toxicity 
when large doses are administered (Raper, Yudkoff et al. 2002), it is important to note that 
safety has been never a limiting issue in cancer trials (Kanerva and Hemminki 2005; Vattemi 
and Claudio 2006). Further, there are exciting preliminary results suggesting efficacy (Khuri, 
Nemunaitis et al. 2000; Sandmair, Loimas et al. 2000; Schuler, Herrmann et al. 2001; 
Immonen, Vapalahti et al. 2004; Xia, Chang et al. 2004; Peng 2005). 
Importantly, the feasibility of gene therapy for correction of disease phenotypes has been 
demonsrated in other fields of medicine  (Isner and Asahara 1999; Cavazzana-Calvo, Hacein-
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Bey et al. 2000; Kay, Manno et al. 2000; Hacein-Bey-Abina, Le Deist et al. 2002). What these 
successes shared in common is the rational approach investigators took for incrementally 
developing their gene delivery tools. Thus, the clinical breakthroughs were based on advances 
in vector development. It remains to be seen if consistent improvements in cancer gene 
therapy reagents can eventually deliver similar clinical success. In that regard, the key issue 
remains improving tumor transduction. Fortunately, we have increasingly powerful tools to 
address this problem, including replication competent systems, infectivity enhancement and 
targeting strategies.
One other obstacle remains as the limited possibility to interact with viral replication in vivo 
after administration. Thus, treatment for viral side effects was only symptomatic so far.  With 
chlorpromazine and apigenin replication of adenoviruses could be desreased in vitro and in 
vivo, theretofore possible viral toxicity in a clinical trial treated causally (Kanerva, in press). 
9. Conclusions 
Current treatment options are limited for many types of human carcinomas and especially 
therapy of advanced disease is often palliative. In recent decades, we have seen improvements 
in the treatment of patients with early disease,  due to aggressive adjuvant chemotherapy 
regimens, refined radiotherapy and advanced operative techniques. However, benefit for 
advanced stage cancer patients have been less dramatic. Also, the toxicity of many current 
treatments remains significant. Thus, there is a need for new and innovative therapeutic 
approaches, which may be able to overcome these limitations. Although gene therapy has 
proven to be a potential candidate, and preliminary evidence of clinical safety and efficacy 
exist, utility, there are still obstacles to overcome. Considering the synergistic or additive 
effect many gene therapy approaches have with existing treatments such as radiation or 
chemotherapy, it is likely that the first routine clinical applications will be combination 
treatments. Further, it is noteworthy that the side effect profile of adenoviral treatments seems 
to have little or no overlap with radiation or chemotherapy.  
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Table 1. Cancer trials with conditionally replicating adenovirusesa
Approach Phase Patients Max. dosef Routec Diseased Ref. 
wild type Ad 
(various 
serotypes) 
ndb 30 ndh it, ia, iv cervical ca. 
(Smith, Huebner et al. 
1956) 
ONYX-015 I 22 1x1011 PFU it SCCHN 
(Ganly, Eckhardt et al. 
2000) 
ONYX-015 I 23 1x1011 PFU it pancreas ca. 
(Mulvihlll, Warren et 
al. 2001) 
ONYX-015 I 10 2x1013 VP iv 
ca. metastatic to 
lung 
(Nemunaitis, 
Cunningham et al. 
2001) 
ONYX-015 I 16 
1x1013 VP/d 
x5d 
ip ovarian ca. (Kirn 2001) 
ONYX-015 I 16 
1x1011
PFU/d x5d 
ip ovarian cancer 




I 9 1x1012 VP it prostate ca. 
(Khil, Aguilar-
Cordova et al. 2001) 
CV706 I 20 1x1013 VP it prostate ca. 
(DeWeese, Drew et al. 
2001; DeWeese, van 
der Poel et al. 2001) 
ONYX-015 I-II 33 2x1012 VP iha 
colorectal (and 
other GI) ca. 
metastatic to 
liver 
(Reid, Galanis et al. 
2001) 
dl1520e +  
5-FU (in 
Phase II) 




and GI ca. 
metastatic to 
liver 
(Habib, Sarraf et al. 
2001) 





(Nemunaitis, Ganly et 
al. 2000; Nemunaitis, 






PFU/d x 5d 
it SCCHN 








PFU/d x 5d 
it SCCHN 
(Lamont, Nemunaitis 









(Hecht, Bedford et al. 
2003) 







(Hamid, Varterasian et 
al. 2003) 




et al. 2003) 
H101 





VP/d x 5d 
i.t. SCCHN 
(Xia, Chang et al. 
2004) 
CG7870 I 23 6X1012 VP i.v. 
Metastatic
prostate cancer 
(Small, Carducci et al. 
2006) 
Total  528     
a An attempt was made to include most published cancer gene therapy clinical trial with oncolytic 
adenoviruses. For a complete listing of gene therapy trials, see (http://www4.od.nih.gov/oba/rac/clinicaltrial.htm; 
http://www.wiley.com/genetherapy/clinical/) 
b nd = not determined 
c iv = intravenous, ia. intra-arterial, it = intratumoral, ip = intraperitoneal, iha = intrahepatic artery 
d ca. = cancer, SCCHN = squamous cell cancer of the head and neck, GI = gastrointestinal 
e dl1520 is original name of ONYX-015, also known as CI-1042. 
f refers to maximum dose administered per cycle if multiple cycles were used. Often, maximum 
tolerated dose was not reached. VP = viral particles. PFU = particle forming (infectious) units. 
g TK = herpes simplex virus thymidine kinase, CD = cytosine deaminase 
h not determined with methodology comparable to current assays 
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AIMS OF THE STUDY 
This study was performed in order to develop new treatment modalities for gynecologic 
cancer patients, who have metastaciesed disease and often not benefit any more from current 
treatment options. Adenoviral Gene Therapy was utilized and a new generation of vectors 
developed.
Specific Aim #1: To measure expression of the flt-1 promoter in different 
gynecologic cancer cell types and to evaluate its potential usefulness for 
teratocarcinoma (I)
Specific Aim #2: To evaluate replication and oncolytic potency in vitro and in 
vivo of Ad5- 24RGD for treatment of ovarian cancer (II)
Specific Aim #3: To evaluate oncolytic potency in vitro and in vivo of Ad5-
24RGD for cervical cancer, to study biodistribution and to assess infectivity 
and toxicity to human peripheral blood mononuclear cells (III)
Specific Aim #4: To construct advanced generation triple targeted oncolytic 
adenoviruses featuring the cox-2 promoter, E1A transcomplementation and 
serotype chimerism, to measure their oncolytic potency for ovarian cancer 
cells in vitro and in vivo and to study replication of the agents in vivo (IV) 
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MATERIALS AND METHODS 
Detailed description of the used methodology can be found in the original publications. 
1. Cell lines and primary cells (I-IV) 
Table 2. The list of human cell lines used in this study 
Cell line Description Used in 
293 Transformed embryonic kidney cells I, II, III, IV 
911 Transformed embryonic retinoblasts IV 
A549 Lung adenocarcinoma II, III, IV 
ES-2 Ovarian adenocarcinoma IV 
Hey Ovarian adenocarcinoma IV 
OV-4 Ovarian adenocarcinoma IV 
SKOV-3.ip1 Ovarian adenocarcinoma IV 
NCCIT Testicular teratocarcinoma I 
NTERA-2 Testicular teratocarcinoma I 
PA-1 Ovarian teratocarcinoma I 
F9 Murine ovarian teratocarcinoma I 
AU565 Mammary gland adenocarcinoma I 
GI-101A Mammary gland adenocarcinoma I 
ZR-75-1 Ductal breast cancer I 
C33A Squamous cervical carcinoma III 
Caski Squamous cervical carcinoma III 
Hela Cervical adenocarcinoma III 
SiHa Squamous cervical carcinoma III 
BEAS-2B Lung epithelial cells I 
BT474 Mammary adenocarcinoma IV 
FHS173WE Fibroblast IV 
HMEC Mammalian endothelial cells IV 
HUVEC Umbilical vein endothelial cells III 
nHEPs Clonetics™ Human Hepatocytes IV 
Cell lines were subcultered according to the providers recommendations and not used with 
passage numbers above thirty. 
Primary ovarian adenocarcinoma cells were purified by an immunomagnetic-based method 
from malignant ascites fluid samples from patients undergoing a procedure for ovarian cancer 
at the University of Alabama at Birmingham Hospital (Barker, Casado et al. 2001). Briefly, 
ovarian cancer cells were bound with a murine anti-TAG-72-antibody (CC-49, a generous gift 
from Dr. J. Schlom, National Institute of Health, Bethesda, MD) and then collected with 
magnetic beads coated with anti-mouse-IgG (Pan Mouse IgG Dynabead, Dynal AS, Oslo, 
Normway) (II). 
Analysis and creation of spheroids from primary ovarian carcinoma cells (II) is detailed 
elsewhere (Lam, Kanerva et al. 2001). Briefly, purified unpassaged cells were incubated 
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overnight in a 3% agar coated flask on a rocker to form spheroids, ie. three-dimensional 
clusters of cells. The spheroids were resuspended and used for experiments. 
Ficoll-Hypaque separated normal donor peripheral blood mononuclear cells (PBMC) were 
obtained from fresh citrated blood. Blood was mixed with PBS (Mediatech, Herndon, VA) 
and underlayered with Histopaque®-1077 (Sigma Diagnostics, St. Louis, MO) for gradient 
centrifugation. After two washing cycles with PBS, viable PBMCs were counted with Trypan 
Blue staining (Mediatech) and cells were dispensed into round bottom 96 well plates for 
incubation in RPMI 1640 medium containing 2 mM L-glutamine (Mediatech) and 10% FBS 
(HyClone).
2. Adenovirus vectors and replicating adenoviruses (I-IV) 
Table 3. The list of adenovirus vectors used in this study 
Virus Description Used in 
Ad5flt-1luc E1-deleted, a luc gene under the flt-1 promoter in place 
of E1 
I
AdCMVluc1 E1-deleted, a luc gene under the CMV promoter in 
place of E1 
I
Ad5flt-1LacZ E1-deleted, a lacZ gene under the flt-1 promoter in 
place of E1 
I
Ad5CMVLacZ E1-deleted, a lacZ gene under the CMV promoter in 
place of E1 
I
Ad5lucRGD E1-deleted, a luc gene under the CMV promoter in 
place of E1, RGD-4C modification in the HI loop of 
the knob domain 
II, III 
Ad5/3luc1 E1-deleted, a luc gene under the CMV promoter in 
place of E1, chimeric fiber with the tail and shaft from 
Ad5 and the knob domain of Ad3 
IV
Table 4. The list of CRAds used in this study 
Virus Description Used in 
Adwt300 wildtype adenovirus III, IV 
Ad5RGD RGD-4C modification in the HI loop of the knob 
domain 
II
Ad5- 24RGD 24-bp deletion in CR2 of E1A, RGD-4C modification 
in the HI loop of the knob domain 
II, III 
Ad5/3- 24 24-bp deletion in CR2 of E1A, chimeric fiber with the 
tail and shaft from Ad5 and the knob domain of Ad3 
IV
Ad5/3cox2LE1 E1A under cox2L promoter, chimeric fiber with the tail 
and shaft from Ad5 and the knob domain of Ad3 
IV
Ad5/3cox2Ld24 24-bp deletion in CR2 of E1A under the cox2L 
promoter, chimeric fiber with the tail and shaft from 
Ad5 and the knob domain of Ad3 
IV
Ad5/3cox2Ld2d24 24-bp deletion in CR2 with additional 6-bp deletion of 
E1A under the cox2L promoter, chimeric fiber with the 
tail and shaft from Ad5 and the knob domain of Ad3 
IV
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Ad5/3cox2ME1 E1A under the cox2M promoter, chimeric fiber with 
the tail and shaft from Ad5 and the knob domain of 
Ad3
IV
Ad5/3cox2Md24 24-bp deletion in CR2 of E1A under the cox2M 
promoter, chimeric fiber with the tail and shaft from 
Ad5 and the knob domain of Ad3 
IV
Ad5/3cox2Md2d24 24-bp deletion in CR2 with an additional 6-bp deletion 
of E1A under the cox2M promoter, chimeric fiber with 
the tail and shaft from Ad5 and the knob domain of 
Ad3
IV
Table 5. The plasmids used for cloning the viruses 
Plasmid Description Used in 
pShuttle
GL3Bcox-2pL 





Shuttle plasmid containing cox2M promoter driving 
GL3B
IV
pSE1 Shuttle plasmid containing wild type E1A IV 
pSE1d24 Shuttle plasmid containing 24-bp deletion in CR2 of 
E1A
IV
pSE1d2d24 Shuttle plasmid containing 24-bp deletion in CR2 with 
additional 3-bp deletion in E1A 
IV
pTU5/3 E1-deleted Ad5 genome with chimeric fiber with the 
tail and shaft from Ad5 and the knob domain of Ad3 
IV
2.1 Construction of cox-2 CRAds (IV) 
The different CRAds were constructed by digesting pShuttleGL3Bcox-2pL and 
pShuttleGL3Bcox-2M with KpnI and HindIII, respectively, to achieve the different cox-2 
promoter sequences. pSE1, pSE1d24 and pSE1d2d24 were digested with XhoI and NotI to 
remove the natural E1 promoter. After blunt-ending with T4-Polymerase the two different 
cox2 promoter sequences were included into the different pSE shuttles. Direction of the 
inserted promoter was checked by PCR. The viral backbone was rescued with PacI digested 
pTU-5/3, which includes GFP and luciferase instead of E1. Specifically, the six different PacI 
digested pSEs were cotransfected with the digested pTU-5/3 into 911 cells. Plaques were 
picked 7 to 20 days after infection and checked for presence of the expected promoter-E1 
combination and Ad5/3 fiber modification as well as absence of wt-E1 and GFP by PCR.  
2.2 High titer production of viruses (I-IV) 
Propagation of the adenovirus vectors and CRAds was performed on 293 and A549 cells, 
respectively. All viruses were purified on cesium chloride gradients. The VP concentration 
was determined at 260 nm, and standard plaque assay on 293 cells was performed to 
determine infectious particles. 
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3. In vitro experiments (I-IV)
3.1 Luciferase assay (I)
Cell lines were plated on day 1 at 25,000 cells per well on 24-well plates in 1 ml growth 
media (GM). On day 2, cells were infected with 5, 50 or 500 PFU/cell for 2 h in 200 μl 2% 
GM on a rocker. Afterwards, cells were washed once with 1 ml PBS and 1 ml GM was added 
per well. After 24 hours the GM was removed, cells were lysed with 200 μl lysis buffer 
(Reporter Lysis Buffer, Promega, Madison, WI) and freeze-thawed once. 20 μl of these 
samples was mixed with 100 μl of luciferase assay reagent (Reporter Lysis Buffer, Promega, 
Madison, WI) and measured with Berthold Lumat LB9501. Standardization was 
accomplished by setting the values obtained with CMV promoter as 100% for each cell line.
3.2 LacZ-staining (I)
Cell lines were plated on day 1 at 50,000 cells per well on 24-well plates in 1 ml GM. On day 
2, cells were infected with 500 PFU/cell for 2 h in 200 μl 2% GM on a rocker. Afterwards, 
cells were washed once with 1 ml PBS and 1 ml GM was added per well. After 24 hours, the 
GM was removed and cells were washed twice with PBS. Cells were fixed for 15 min with 
0.5% glutaraldehyde and washed again twice with PBS. Cells were stained for 2 1/2 hours 
with standard X-gal solution (containing 40 μl 2% X-gal, 10 μl 0.3 M potassium ferricyanide, 
10 μl 0.3 M potassium ferrocyanide and 940 μl PBS per ml), washed again for 10 min with 
PBS and fixed a second time with 10% buffered formaline for 30 min. Pictures were taken by 
bright field microscopy at 10x magnification. 
3.3 RT-PCR (I) 
RNA of cells was extracted with RNeasy mini prep kit (Qiagen, Valencia, CA), treated with 
Deoxyribonuclease I (Life Technologies, Rockville, MD) for 30 min and RT-PCR of 90 ng 
RNA each was performed with the OneStep RT-PCR Kit (Qiagen, Valencia, CA) using  the 
following primers: Flt-1 sense: 5’-TGC TTG AAA CCG TAG CTG G-3’, Flt-1 antisense:  5’-
GGT GCC AGA ACC ACT TGA TT-3’; GAPDH sense: 5’-TCC CAT CAC CAT CTT 
CCA-3’; GAPDH antisense: 5’-CAT CAC GCC ACA GTT TCC-3’. Preliminary serial 
dilution assays were used to determine the linear range of amplification for the genes under 
investigation.
3.4 Crystal violet assay (II)
Cells were plated at 500,000 cells per well on 6-well plates and infected with 0, 0.1, 1 or 10 
VP/cell for 1 h, followed by washing. Growth medium with 5% FBS was changed every other 
day. On day 10 (PA-1), day 14 (Hey and SKOV3.ip1) or day 17 (OV-4), respectively, crystal 
violet staining was performed as described (Hemminki, Dmitriev et al. 2001).  
3.5 Mitochondrial oncolysis assay (II, III, IV) 
MTS assay was performed as described (Bauerschmitz, Lam et al. 2002). Briefly, with 
ovarian cancer cell lines, cells were plated at 15,000 cells per well on 96-well plates and 
infected with 0, 0.1, 1 or 10 VP/cell for 1 h in 50 μl medium (2% FBS) on a rocker. Cells 
were incubated in medium with 5% FBS, which was changed every other day. On day 8 (PA-
1), day 15 (Hey and SKOV3.ip1) or day 16 (OV-4), plates were washed twice, cells were 
lysed (Reporter Lysis Buffer, Promega, Madison, WI) and freeze-thawed once. Protein 
concentration was measured with the DC Protein Assay system (Bio-Rad Laboratories, 
Hercules, CA). 
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Cervical cancer cell lines Caski, Hela, SiHa and C33A cells were infected as above. Cells 
were incubated in medium with 5% FBS, which was changed every other day. On day 13 
(SiHa and C33A) or day 14 (Caski and Hela), MTS assay (CellTiter96®Aqueous One 
Solution Reagent, Promega, Madison, WI) was performed. 
For the triple targeted oncolytic adenoviruses, cells were infected as above and incubated in 
medium with 5% FBS, half of which was changed every other day. On day 7 (nHEPs), day 9 
(A549, BT474), day 10 (FHS173WE), day 14 (SKOV3.ip1), day 17 (OV-4) or day 18 (Hey 
and ES-2), MTS assay (CellTiter96®Aqueous One Solution Reagent, Promega, Madison, WI) 
was performed. 
3.6 Quantitative PCR (II, III, IV) 
Primary ovarian adenocarcinoma cells (II) were purified from malignant ascites samples as 
described (Barker, Casado et al. 2001). Analysis and creation of spheroids from primary 
ovarian carcinoma cells is detailed elsewhere (Lam, Kanerva et al. 2001). Briefly, purified 
unpassaged cells were incubated overnight in a 3% agar coated flask on a rocker to form 
spheroids, ie. three-dimensional clusters of cells. The spheroids were resuspended and 
infected with 1000 VP/cell of Ad5- 24RGD. Next day, spheroids were divided into 5 equal 
aliquots of 1 x 105 cells, which were collected daily. DNA was extracted with QIAamp DNA 
Mini Kit (Qiagen Inc., Valencia, CA), and quantitative PCR for the E1 gene was performed 
with Lightcycler® methodology as described (Hemminki, Belousova et al. 2001). In order to 
display the negative control, readings below the assay’s detection limit were set as 1 and other 
results are displayed relative to this control.  
105 cells/well (III, IV) were cultured on 96-well plates and infected with 0, 1 and 10 VP/cell. 
Quadruplet wells were collected after 2, 4, 6, 8 and 10 days and snap-frozen. DNA was 
extracted with DNeasy Tissue Kit (Qiagen Inc., Valencia, CA) and quantitative PCR for the 
E4 gene was performed as described.(Hemminki, Belousova et al. 2001) E4 copy numbers 
were normalized to human -actin.
Table 6. Primers and probes for quantitative PCR 
Adenoviral E1 Used in 
Forward 5’-AACCAGTTGCCGTGAGAGTTG-3’ II 
Reverse 5’-CTCGTTAAGCAAGTCCTCGATACA-3’ II 
Probe 5’-CACAGCCTGGCGACGCCCA-3’ II 
Adenoviral E4 
Forward 5’-GGAGTGCGCCGAGACAAC-3’ III, IV 
Reverse 5’-ACTACGTCCGGCGTTCCAT-3’ III, IV 
Probe 5’-TGGCATGACACTACGACCAACACGATCT-3’ III, IV 
Human ß-actin 
Forward 5’-TAAGTAGGCGCACAGTAGGTCTGA-3’ II, III, IV 
Reverse 5’-AAAGTGCAAAGAACACGGCTAAGT-3’ II, III, IV 
Probe 5’-CAGACTCCCCATCCCAAGACCCCA-3’ II, III, IV 
3.7 Oncolysis assay for peripheral blood mononuclear cells (PBMC) (III) 
On day 1, PBMC and C33A cells were plated at 150,000 cells per well on 96-well-plates with 
100 μl medium containing virus at 0, 10, 100 or 1000 VP/cell. Cells were cultured at 37°C 
and 5% CO2. MTS assay was performed on days 4 and 6. Results are displayed in proportion 
to uninfected cells.
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3.8 Detection of viral replication in PBMC (III) 
105 PBMC/well were cultured with 5 μg/ml Phytohemagglutinin-P (PHA-P, Sigma), 100 
IU/ml recombinant human interleukin 2 (IL-2, Proleukin, Chiron, Emeryville, CA) or no 
stimulation, and infected with 1000 VP/cell of Ad5- 24RGD, Ad5- 24E3 or Ad5lucRGD, at 
37°C with 7% CO2. Quadruplet wells were collected 1 h, 4 and 6 days later and frozen. DNA 
was extracted with DNeasy Tissue Kit (Qiagen Inc., Valencia, CA) and quantitative PCR for 
the E4 gene was performed as described.(Hemminki, Belousova et al. 2001) E4 copy numbers 
were normalized to human -actin.
3.9 Tritiated thymidine uptake in PBMC (III) 
PBMC were plated in quadruplicate with 105 cells/well and stimulated with 5 μg/ml PHA-P or 
100 IU/ml IL-2. The mixture was infected with 1000 VP/cell of Ad5- 24RGD, Ad5- 24E3 
or Ad5lucRGD in a total volume of 200 μl. Cells were cultured at 37°C with 7% CO2. On 
days 3 and 5, cells were pulsed with 1 Ci of tritiated thymidine (New England Nuclear, 
Boston, MA) 18 - 20 h prior to harvesting with a Skatron Micro96 Harvester, and cell-
incorporated tritium was assessed using a Packard Matrix 9600 Beta Counter. Results were 
expressed in counts per minute and converted to a stimulation index relative to the wells with 
no stimulation and no virus.
3.10 Detection of viral replication with TCID50 (IV) 
1.5x104 cells/well of SKOV3.ip1 or BT474 were cultured on 96-well plates and after 24 hours 
infected with 10 VP/cell. Quadruplet wells (cells and supernatant) were collected after 2, 4, 6 
and 8 days and carried over to 48-well plates. Cells were lysed with three freeze-thaw cycles. 
TCID50 was performed as published with 104 cells/well of 293 cells with dilutions up to 10-13 
and detected after 10 days REF. 
4. Preclinical in vivo evaluation of viruses 
4.1 Therapeutic ovarian carcinoma model (II)
CB17 SCID mice (n=11/group) were injected with 1 x 107 SKOV3.ip1 cells ip. on day 0. On 
days 4, 5 and 6, mice were injected ip. with 1 x 1010 or 5 x 108 VP of Ad5- 24RGD,
Ad5lucRGD (non-replicative control) or no virus. The virus was diluted with Opti-MEM into 
1 ml in each case. Mice were inspected daily and euthanasia was performed in case of 
discomfort or distress. Survival data was plotted into a Kaplan-Meier curve and, using the 
LIFETEST procedure in SAS v.8.2 VENDOR, and the Ad5- 24RGD group was compared to 
the other groups with the log-rank test. The distribution of the data best fit the Weibull model, 
which was utilized for individual comparisons between the Ad5- 24RGD groups and 
controls, using the chi-square test of SAS v.8.2 LIFEREG procedure. 
4.2 Cervical cancer animal model (III) 
Female CRL.Nu/Nu mice (Charles River Laboratories, Wilmington, MA) (n=5/group) were 
injected in both flanks with 1x107 C33A cells subcutaneously and tumors were allowed to 
grow. After 21 days viruses were injected i.t. or i.v., and tumor size was measured during 
follow up. The viruses were diluted with Opti-MEM into 200μl in each case. Mice were 
inspected daily and euthanasia of the complete group was performed in case of high tumor 
load, evident pain or distress. Studies were approved by the UAB Institutional Review Board.
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4.3 Biodistribution of intravenous Ad5- 24RGD (III) 
C33A tumors were inoculated in nude mice as above (n=3/group). At day 21, 5x1010 VP of 
Ad5- 24RGD diluted in 200μl OptiMEM was injected i.v. into each mouse. On days 1 and 7 
after injection, liver, spleen, kidneys, heart, lungs and tumors were collected and snap-frozen 
with dry-ice/ethanol. DNA was extracted and E4 copy number was determined as above. 
4.4 In vivo imaging and survival analyses (IV) 
Hey ovarian cancer cells were grown s.c. in nude mice and when tumors were ca. 10 mm3,
3x108 VP of each CRAD was injected on 3 consecutive days. Tumor size was followed and 
plotted relative to initial size. 3x108 VP of luciferase expressing, non-replicating Ad5/3Luc1 
was coinfected with each virus and in vivo luciferase imaging was performed 3 days later. For 
imaging, 4.5 mg of d-luciferin (Promega) was injected i.p in 100ul of 0% growth medium and 
images were captured with the IVIS 100 system using Living Image v. 2.50 (Xenogen inc., 
Alameda, CA). 
SKOV3.ip1 ovarian cancer cells were injected with 107 cells per mouse and tumors were 
allowed to grow intraperitoneally for 7 days. Then 108 VP of Ad300wt, Ad5/3d24 or 
Ad5/3Cox2Ld24 were injected on three consecutive days intraperitoneally and survival was 
monitored. 
5. Statistics (II, III, IV) 
The ANOVA F-test (II) (SAS v.8.2, SAS Institute, Cary, NC) was performed to see if there 
were differences between the oncolytic potency of the viruses. If there was unequal 
distribution of the results, a two-sided t-test was utilized to assess statistical significance in 
comparison to the non-replicating virus. 
An analysis of the tumor size data (III) was performed using a repeated measures growth 
model with PROC MIXED (SAS Ver. 8.02). Tumor size data was log transformed for 
normality. The effects of treatment group, time and the interaction of treatment group and 
time were evaluated by F tests.  Baseline tumor size was included as a covariate in all models.  
A priori planned comparisons of adjusted differences in predicted treatment means were 
computed by t-statistics averaged over all timepoints. For all analyses a two-sided p value of 
< 0.05 was deemed statistically significant. 
The F-test (IV) was performed to see if there were differences between the oncolytic potency 
of the viruses. If there was unequal distribution of the results, a two-sided t-test was utilized to 
assess statistical significance in comparison to the non-replicating virus, the Delta24 5/3-
chimeric virus without TSP and the wt-virus controls. For all analyses a two-sided p value of 
< 0.05 was deemed statistically significant. In vivo, mean tumor size and standard deviations 
were calculated for each group of animals for each time point. A non-parametric change-point 
test was used to show a systematic change in the pattern of observations as opposed to 
fluctuation due to chance. The Proc Mixed procedure in SAS v.6.12 (SAS Institute, Cary, NC) 
was used to examine the effects of group and time on tumor growth. Pairwise comparisons 
were performed to compare groups.  
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RESULTS AND DISCUSSION 
1.  Transcriptional targeting of teratocarcinoma cells with the flt-1 promoter (I) 
Flt-1, a receptor for vascular endothelial growth factor (VEGF), has been reported to display 
dysregulated expression in both tumor vasculature and tumor cells per se (von Marschall, 
Cramer et al. 2000; Bellamy, Richter et al. 2001; von Marschall, Cramer et al. 2001), 
suggesting that the flt-1 promoter might be a useful candidate to achieve tumor-specific 
transgene expression. 
We demonstrated endogenous flt-1 expression in teratocarcinoma cell lines but not in ovarian, 
breast and cervical carcinoma cell lines. These data suggest that the expression of flt-1 mRNA 
reported in ovarian adenocarcinoma tumor blocks (Abu-Jawdeh, Faix et al. 1996) was likely 
caused by non-teratocarcinoma cells, such as endothelial cells of the tumor vessels. In contrast 
to our findings are the results of Masood et al. (Masood, Cai et al. 2001), who found a variety 
of cancer cell lines positive for flt-1 expression with RT-PCR, including the ovarian 
adenocarcinoma cell line Hey. A possible reason for the discrepancy could relate to the cells 
(eg. passage number) or be associated with the sensitivity of the RT-PCR assays used.  
Although teratocarcinomas are rare tumors and usually treatable with chemotherapy 
(Gershenson 1993; Lu and Gershenson 2005), these findings are of potential interest since 
they represent the first time a promoter has been demonstrated to be active in teratocarcinoma, 
independent of the tissue type it originates from. We saw flt-1 promoter activity irrespective if 
the teratocarcinoma cell was derived from ovarian or testicular tissue. Any promoters that 
retain fidelity when placed in the Ad genome, achieve good levels of transgene expression 
and have a “liver off” phenotype are potentially of clinical utility. The close correlation of 
transgene expression and flt-1 mRNA shown here is further evidence that this promoter has 
the required characteristics. These data suggest that flt-1 could be useful for transcriptionally 
targeting teratocarcinoma. 
The biological reason for the flt-1 promoter activity, we found in teratocarcinoma cells, 
remains unknown. Since teratocarcinomas are derived from undifferentiated, pluripotent early 
embryonal cells and contain cells from endo-, meso- and ectoderm (Damjanov 1993), lack of 
differentiation could be a possible reason for the expression of this promoter normally active 
in mature endothelium. In fact, previous studies suggested cross dependance of flt-1 gene 
expression and differentiation status (Bednarz, Weich et al. 1995; Bednarz, Weich et al. 
1996). To test this hypothesis, we induced artificial differentiation of the teratocarcinoma cell 
lines with retinoid acid and cAMP or valproic acid (Imperiale, Kao et al. 1984; Werling, 
Siehler et al. 2001), followed by infection with a luciferase expressing adenovirus. Although 
we could validate artificial differentiation by observing changes in CMV driven gene 
expression and microscopic appearance of the cells, neither experiment demonstrated an 
association between flt-1 expression and artificially induced differentiation. However, both 
models used here are distinct from natural differentiation processes and thus may offer limited 
insight in this context. 
2. Killing of ovarian cancer cells with conditionally replicating adenovirus Ad5- 24RGD
(II)
In all cell lines, the crystal violet based cell killing assay showed replication of Ad5- 24RGD
and Ad5wtRGD, followed by oncolytic death of cells. In the adenocarcinoma lines (Hey, 
SKOV3.ip1 and Ov-4), the CRAD replicated to similar degree as a virus containing wild type 
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early genes (Ad5wtRGD). For PA-1, a teratocarcinoma line, the oncolytic effect of 
Ad5wtRGD was slightly stronger than Ad5- 24RGD. Ad5LucRGD did not cause oncolysis. 
The crystal violet findings were confirmed with a quantitative assay based on mitochondrial 
activity, which reflects the amount of cells left after replication and oncolysis. When 10 
VP/cell of Ad5- 24RGD was used for infection of Hey, SKOV3.ip1, PA-1 and OV-4 cells, 
11.2%, 46.2%, 73.0% and 46.7% of cells remained alive (as compared to uninfected wells). 
For Ad5wtRGD, the positive control, the results were similar (13.7%, 22.7%, 28.0%, 51.9%). 
Therefore, Ad5- 24RGD has similar oncolytic potential to an E1 wild type virus. 
Ovarian cancer primary cells spheroids provide a useful three-dimensional model for 
assessing replicativity of CRADs. More importantly, they provide a convenient means of 
maintaining primary cells alive in culture, without the confounding effect caused by clonal 
selection pressure involved in passaging and adaptation to cell culture. Spheroids were 
collected 1 thru 5 days after infection and quantitative PCR was performed to detect viral 
copies. One day after infection, 1.13 copies/well were detected, and the number grew 
exponentially to 1,036 – 19,336 – 402,000 – 4,296,000 copies on days 2 - 3 - 4 - 5. Thus, 
Ad5- 24RGD infects and replicates in primary unpassaged ovarian cancer cells. These results 
suggest that Ad5- 24RGD can infect and replicate in ovarian cancer cell lines and primary 
ovarian cancer cells.  
3. Therapeutic efficacy of conditionally replicating adenovirus Ad5- 24RGD in a 
murine model of ovarian cancer (II)
We utilized an orthotopic murine model of ip. ovarian carcinomatosis and treated the mice 
with 3 ip. doses of 1 x 1010 VP of Ad5-D24RGD, the non-replicative Ad5lucRGD or no virus. 
Median survival was 64, 45 and 36 days, respectively and mean survival times for 
Ad5lucRGD and no virus were 45.7 and 37.6 days, respectively. Statistical analysis with the 
log-rank chi-square test indicated that survival was significantly better in animals treated with 
Ad5- 24RGD (P<0.0001). A smaller dose of the viruses (5 x 108 VP/day) was also 
investigated. The median survival was not reached for Ad5- 24RGD. For Ad5LucRGD and 
no virus, the median survival was 40 and 36 days and means were 41.9 and 37.6 days, 
respectively. All mice in the control groups expired before day 60. All mice treated with 5 x 
108 VP of Ad5- 24RGD survived until at least day 61. The log-rank and chi-square tests 
confirmed that survival was significantly better in animals treated with Ad5- 24RGD
(P<0.0001). Interestingly, none of the mice treated with Ad5- 24RGD showed evidence of 
i.p. disease after treatment. Instead, many developed subcutaneous tumors at the site where 
tumor cell injection had been performed, which eventually necessitated sacrificing of the 
animals. This could have been caused by a small number of tumor cells contaminating the 
needle tract during injection of cells. The virus probably had little access to the subcutaneous 
tissue and therefore could not eradicate these cells. It should be noted that no cures or long 
term survival had previously been reported for this aggressive model of ovarian cancer. All 
animals in the control groups expired or were killed due to i.p. tumor growth.  
With the smaller dose of 5 x 108 VP daily for three days used here, ca. 1 x 1012 VP for a 60 kg 
human (w/w) were equaled. dl1520 has been administered to humans i.p. with doses ranging 
from a daily dose of 1 x 1011 to 1 x 1013  VP for 5 consecutive days (Kirn 2001). The results 
of this trial suggest that patients with bulky tumors (>2 cm) experienced dose limiting side 
effects at 1 x 1012 VP x 5, while patients with non-bulky tumors tolerated 1 x 1013 VP x 5 
without toxicity. While comparisons between mouse and human data should be avoided, since 
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human Ads do not replicate in murine tissues to any significant degree, these figures suggest 
that the oncolytic potency of Ad5- 24RGD is sufficient to merit a human trial. 
4. Killing of cervical cancer cells with conditionally replicating adenovirus Ad5- 24RGD
(III)
In all four cervical cancer cell lines tested, the mitochondrial activity based MTS cell killing 
assay showed oncolysis mediated by Ad5- 24RGD and Ad300wt. When 10 VP/cell of Ad5-
24RGD was used for infection of C33A, Caski, Hela and SiHa cells, 0%, 24%, 16.5% and 
34% of cells remained alive as compared to the uninfected control, whereas the wild type 
virus resulted in 0%, 6%, 11% and 29% living cells. Therefore, on cervical cancer cells in 
vitro, Ad5- 24RGD shows similar efficacy to wild type Ad. 
Ad5- 24RGD was also compared to Ad5- 24E3, which is otherwise identical, but has a 
serotype 5 capsid. Similar or improved oncolytic potency was seen on all cell lines studied. 
This is in accord with findings of other investigators and our previous studies, demonstrating 
similar replicativity of CR2 deleted and wild type adenoviruses in tumor cells (Heise, 
Hermiston et al. 2000; Bauerschmitz, Lam et al. 2002).  
5. PBMC can be infected but not lysed by conditionally replicating adenovirus Ad5-
24RGD (III) 
Of special interest for possible human applications of Ad5- 24RGD is the effect on human 
leukocytes. Ad serotype 5 based agents do not effectively infect PBMCs in vivo (Wickham, 
Lee et al. 1997; Goossens, Havenga et al. 2001), although transduction can be forced with 
high titers in vitro (Schranz, Kulcsar et al. 1979; Chen, Ahonen et al. 2002). However, the 
RGD modification could increase the infectivity of PBMCs as these cells have been reported 
to express the relevant integrins (Horvath, Kulcsar et al. 1983). Ad capsids induce clonal 
increases in various PBMC lineages and there is migration of PBMCs to the infection site 
(Schranz, Kulcsar et al. 1979; Horvath, Kulcsar et al. 1983; Higginbotham, Seth et al. 2002). 
Thus, if PBMCs can be infected and sustain replication, there may be potential for 
hematological toxicity.  
Freshly obtained PBMCs displayed no reduction in viability 4 or 6 days after infection with 
up to 1000 VP/cell of Ad5- 24RGD. This dose corresponds with a 1013 VP i.v. dose for a 
human adult with a blood count of 4.3x109 leukocytes/liter, typical for cancer patients after 
chemotherapy (Grover 1996), and could therefore correlate with exposure in a clinical trial 
context. In contrast, the cervical cancer cells that were included as controls, were killed. 
To mimic in vivo activation, PBMCs were infected in vitro with Ad5- 24RGD or controls 
and simultaneously stimulated with recombinant human IL-2 or PHA-P. Tritium 
incorporation was used as a marker of proliferation. On day 4, IL-2 and PHA-P had caused 
significant proliferation regardless of virus infection, although Ad5- 24RGD infected cells 
expanded slightly less. By day 6, these differences were increased indicating a possible toxic 
effect of Ad5- 24RGD. To determine if this was due to virus replication, virus copy number 
was determined in stimulated and unstimulated cells. No replication of any of the viruses was 
detected.
Importantly, we did not see any decrease in the viability of PBMCs following infection with 
Ad5- 24RGD. Further, no replication of the agent was seen in PBMCs regardless of 
stimulation. However, our results suggest that Ad5- 24RGD does interfere with IL-2 or 
PHA-P mediated stimulation. This was especially evident on day 6. The effect may be 
dependent on E1 expression in the cells, as the E1-deleted Ad5lucRGD did not produce 
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similar results. Further, as the isogenic control virus with a wild type adenovirus 5 capsid 
(Ad5- 24E3) did not cause this effect, it seems likely that RGD was required for entry. 
Despite probably entering PBMCs, Ad5- 24RGD was not able to replicate in or kill the cells, 
perhaps due to an intact Rb/p16 pathway or other cell type specific reasons.  
This data is of special interest for possible human applications. It was shown, that Ad serotype 
5 based agents do not effectively infect PBMCs in vivo,(Wickham, Lee et al. 1997; Goossens, 
Havenga et al. 2001) although transduction can be forced with high titers in vitro(Schranz, 
Kulcsar et al. 1979; Chen, Ahonen et al. 2002). However, the inserted RGD modification 
could have increased the infectivity of PBMCs as these cells have been reported to express the 
relevant integrins (Conron, Bondeson et al. 2001). Ad capsids induce clonal increases in 
various PBMC lineages and there is migration of PBMCs to the infection site(Schranz, 
Kulcsar et al. 1979; Horvath, Kulcsar et al. 1983; Higginbotham, Seth et al. 2002). Thus, if 
PBMCs could have been infected and subsequently sustained replication, there would be 
potential for hematological toxicity. Here 1000 VP/cell were used, an amount of virus 
corresponding to about 1013 VP i.v., similar to a CRAD dose tested in clinical trials 
(Bauerschmitz, Barker et al. 2002:Glasgow, 2004 #1833; Kanerva and Hemminki 2005). 
Importantly, we did not see any decrease in the viability of PBMCs following infection with 
Ad5- 24RGD. Further, no replication of the agent was seen in PBMCs regardless of 
stimulation. However, our results suggest that Ad5- 24RGD does interfere with IL-2 or 
PHA-P mediated stimulation, which was especially evident on day 6. The effect may be 
dependent on E1 expression in the cells, as the E1-deleted Ad5lucRGD did not produce 
similar results. Further, as the isogenic control virus with a wild type adenovirus 5 capsid 
(Ad5- 24E3) did not cause this effect, it seems likely that RGD is required for entry. Despite 
probably entering PBMCs, Ad5- 24RGD was not able to replicate in or kill the cells, perhaps 
due to an intact Rb/p16 pathway or other cell type specific reasons.  
Nevertheless, these experiments were designed as a preliminary investigation and further, 
more comprehensive studies are clearly required. Furthermore, while the information from 
preclinical experiments such as performed here, yield interesting and important data, clinical 
studies will ultimately determine the safety and efficacy of novel agents.    
6. Biodistribution and in vivo replication of conditionally replicating adenovirus Ad5-
24RGD (III) 
For performing a clinical trial, the best available preclinical assays should be used for 
evaluation of not only the efficacy, but also the safety of agents. Comprehensive murine 
toxicity studies with human serotype CRADs are not optimal, as human Ads do not 
productively replicate in mice (Higginbotham, Seth et al. 2002). Nevertheless, biodistribution 
can be assessed.  
Eighteen hours after i.v. injection of Ad5- 24RGD into mice with s.c. tumors, virus was 
detected mainly in liver, spleen (35% compaired to the liver dose), lungs (25%) and tumor 
(14%), whereas heart (1.8%) and kidneys (1.4%) were infected with a lower amount. The 
liver to tumor ratio of virus copies was 7:1. On day 7 after injection, a 558-fold relative 
amplification of the virus within the tumor was found, suggesting i.t. viral replication in vivo.
The dose of virus was chosen to allow direct comparison to previous experiments which were 
performed with E1-deleted Ads (Kanerva, Wang et al. 2002). Our results are well in accord 
with the data obtained with the RGD modified vector. As expected, the liver is the preferred 
organ for viral infection after i.v. injection. In contrast to i.p. injection, where spleen and liver 
have a similar viral uptake (Kanerva, Wang et al. 2002), only 35% of the liver dose reached 
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the spleen after i.v. injection. And whereas lung infection is insignificant after i.p. injection, 
25% of the liver dose was found there after i.v. injection. 
Human Ads do not productively replicate in most non-human cells and therefore it was an 
expected finding to see lack of replication of the agent in murine tissues (Higginbotham, Seth 
et al. 2002). In the liver, the virus DNA increased 3.5 fold (not significant), which may reflect 
a low degree of DNA multiplication without virion production. 
More relevant toxicity studies could be performed if syngeneic model systems can be 
developed (Higginbotham, Seth et al. 2002). However, such systems would not be applicable 
to human viruses. Nevertheless, the respective non-human viruses could be constructed. Most 
recent publications reported replication of human adenoviruses to a certain degree in cottan 
rats, Syrian hamsters and swine (Toth, Spencer et al. 2005; Jogler, Hoffmann et al. 2006; 
Thomas, Spencer et al. 2006), but must be further investigated.
7. Therapeutic efficacy of conditionally replicating adenovirus Ad5- 24RGD in a 
murine model of disseminated cervical cancer (III)
The ultimate preclinical tests of experimental therapeutics are in vivo models. Here, we  
initially utilized as a proof of concept a murine model that mimics a strict locally recurrent 
advanced cervical cancer, a form of disease that would probably be accessible to local 
injection. Advanced C33A tumors were allowed to grow on the flancks. Then, mice were 
randomized into 6 groups and treated with three i.t. doses of either 107, 108, 109 or 1010 VP of 
Ad5- 24RGD, 1010 VP of the E1-deleted Ad5lucRGD or no virus in 200 μl OptiMEM. 
Treatment with the non-replicating Ad5lucRGD or without virus did not show an effect on 
tumor growth. Ad5- 24RGD at 1010 VP gave a significantly improved therapeutic effect over 
Ad5lucRGD and mock (both P < 0.0001). The same was true when the dose was 109 VP (P <
0.0001 versus Ad5lucRGD and P = 0.0004 versus mock) or 108 VP (P = 0.0002 versus
Ad5lucRGD and P = 0.0190 versus mock). Interestingly, even the smallest dose injected gave 
a therapeutic effect in this aggressive model. The larger doses resulted in slightly higher 
efficacy. Converted weight/weight into a human dose, 107 VP would be approximately 
2x1010, well below the 1x1013 VP of another CRAD that has been administered i.t. to humans 
without dose limiting side effects (DeWeese, van der Poel et al. 2001). 
The most difficult form of cervical cancer to treat is disseminated disease. For such 
applications, systemic administration is necessary. Therefore, we evaluated i.v. injection of 
Ad5- 24RGD into mice bearing multiple tumors. Then, the mice were injected i.v. either with 
a single dose of 1010, three doses of 3x1010 or a single dose of 1011 VP of Ad5- 24RGD. The 
controls were a single dose of 1011 VP of E1 deleted Ad5lucRGD and no virus.  
I.v. injection of 1010 VP Ad5- 24RGD resulted in a slight reduction in tumor growth. At this 
dose, Ad5- 24RGD had an undramatic but statistically significant effect on tumor growth (P
= 0.0002 versus Ad5lucRGD and P = 0.0125 versus mock). This is in accord with previous 
studies, where 1-2 x 1010 VP has been suggested as the threshold for uptake by the Kupffer 
cells of the liver (Alemany, Suzuki et al. 2000; Tao, Gao et al. 2001; Kanerva, Wang et al. 
2002). In other words, only doses larger than this result in effective circulation of virus.  
Fittingly, 1011 VP resulted in significant reduction of tumor growth, irrespective of whether a 
single or a split dose was used. The triple dose gave a more pronounced therapeutic effect 
over no virus, Ad5lucRGD or the lower single dose (all P < 0.0001). The same was true for 
the higher single dose (all P < 0.0001). There was no difference in efficacy between the triple 
and the higher single dose (P = 0.3681). Therefore, we were able to achieve therapeutic 
benefit utilizing systemic treatment in a murine model of disseminated cervical cancer. 
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There is limited data available on i.v. administration of CRADs to humans, but the trials that 
have been completed suggest good safety (Nemunaitis, Cunningham et al. 2001; Reid, 
Galanis et al. 2001; DeWeese, Arterbery et al. 2003; Hamid, Varterasian et al. 2003; Hecht, 
Bedford et al. 2003; Xia, Chang et al. 2004; Small, Carducci et al. 2006). The lack of 
demonstration of efficacy in early trials may be related to the low replicativity of the agents 
used (Barker and Berk 1987; Bischoff, Kirn et al. 1996; Hay, Shapiro et al. 1999), perhaps 
compounded by variable expression of CAR on target cells. In contrast, Ad5- 24RGD
features replicativity similar to wild type, enhanced infectivity via metastasis associated 
integrins (Grill, Van Beusechem et al. 2001; Kawaguchi, Hosotani et al. 2001; Wesseling, 
Bosma et al. 2001; Hemminki, Zinn et al. 2002; Nakamura, Sato et al. 2002; Su, Liu et al. 
2002) and independence from CAR. Considering the high prevalence of circulating 
neutralizing anti-adenovirus antibodies (Hemminki 2002), the capacity of RGD modified Ads 
to partially avoid pre-existing neutralizing antibodies may be useful (Blackwell, Li et al. 
2000; Hemminki, Zinn et al. 2002). It is not known if the threshold effect associated with i.v. 
administration to mice applies to humans, or what the threshold dose might be. Obviously, 
this is of utmost importance for systemic application of CRADs and needs to be studied. 
For performing a clinical trial, the best available preclinical assays should be used for 
evaluation of not only the efficacy, but also the safety of agents. Comprehensive murine 
toxicity studies with human serotype CRADs are not optimal, as human Ads do not 
productively replicate in mice (Hemminki, Kanerva et al. 2003). Nevertheless, biodistribution 
can be assessed. 18 h after i.v. injection, the liver to tumor copy number ratio was 7:1. 6 days 
later, a 558-fold i.t. copy number increase was seen. The dose of virus was chosen to allow 
direct comparison to previous experiments which were performed with E1-deleted Ads 
(Kanerva, Wang et al. 2002). Our results are well in accord with the data obtained with the 
RGD modified vector. As expected, the liver is the preferred organ for viral infection after i.v. 
injection. In contrast to i.p. injection, where spleen and liver have a similar viral 
uptake(Kanerva, Wang et al. 2002), only 35% of the liver dose reached the spleen after i.v. 
injection. And whereas lung infection is insignificant after i.p. injection, 25% of the liver dose 
was found there after i.v. injection. More relevant toxicity studies could be performed if 
syngeneic model systems can be developed (Hemminki, Kanerva et al. 2003). However, such 
systems would not be applicable to human viruses. Nevertheless, the respective non-human 
viruses could be constructed. 
These data suggest, that Ad5- 24RGD can successfully infect tumor cells and replicate in
vivo, even when the virus is injected i.v. Of note, none of the mice died or displayed visual 
evidence of toxicity after i.t. or i.v. viral injection.  
8. Effect of combination of promoter and deletion on selectivity and efficacy of 
conditionally replicating adenoviruses (IV) 
We constructed six novel viruses, each controlled by long or medium variants of the cox2 
promoter (Yamamoto, Alemany et al. 2001; Yamamoto, Davydova et al. 2003). These 
promoter variants have been evaluated previously for potential utility for ovarian cancer gene 
therapy (Casado, Gomez-Navarro et al. 2001; Barker, Coolidge et al. 2003). The cox2 
promoter has been suggested a potentially useful tumor specific promoter given low 
expression in livers of mice and relatively high expression in many tumor types including 
ovarian cancer (Casado, Gomez-Navarro et al. 2001; Barker, Coolidge et al. 2003; 
Yamamoto, Davydova et al. 2003; Kanerva, Bauerschmitz et al. 2004). Three variants of the 
central adenoviral replication regulator gene (E1A) were used: wild-type E1, a Delta24-
modified version (24 bp deletion in Rb binding site of E1A) or a Delta2-Delta24-modified 
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version (additional incorporation of a 3 bp deletion – encoding for second amino acid of E1A, 
ie. the p300 binding site (Nettelbeck, Rivera et al. 2002). The specificity and efficacy of 
Delta24-modified viruses have been demonstrated previously (Fueyo, Gomez-Manzano et al. 
2000; Bauerschmitz, Lam et al. 2002; Nettelbeck, Rivera et al. 2002; Kanerva, Zinn et al. 
2003; Lam, Bauerschmitz et al. 2003; Lam, Kanerva et al. 2004). Theoretically, additional 
control over E1A might result in higher specificity allowing an improved therapeutic window 
(difference in replication between normal and cancer cells). An earlier publication suggested 
tumor specificity for the Delta2 mutation in the context of cervical cancer cells (Balague, 
Noya et al. 2001). All viruses constructed here were infectivity enhanced with the adenovirus 
type 3 fiber knob in the adenovirus type 5 fiber shaft. Our previous work suggests that this 
may be the “best currently available” transductional targeting moiety for ovarian cancer 
(Kanerva, Mikheeva et al. 2002; Kanerva, Wang et al. 2002; Kanerva, Zinn et al. 2003; Lam, 
Kanerva et al. 2004).  
We compared two variants of the cox2 promoter; a longer version (cox2L, 1554 bp) which 
has been reported more specific, and a medium version (cox2M, 988 bp), which might feature 
a higher expression level (Yamamoto, Alemany et al. 2001; Yamamoto, Davydova et al. 
2003). Here, we saw similar results in that the cox2L promoter was slightly more specific, 
especially in the context of wild type E1A. In tumor cells we did not see significant 
differences between the promoters, but there seemed to be a tendency for the cox2M promoter 
to allow slightly higher rates of cell killing when driving wild type E1 or driving Delta2-
Delta24.
Fig. 6. Schematic illustration of the six different triple-targeted selectively oncolytic 
adenoviruses
When the different combinations of promoter with E1 variants were compared, Delta24 
resulted in the most promising data. The rates of oncolysis were higher (cox2L) or similar 
(cox2M) to wild type E1A. Other studies have corroborated the high replicativity of Delta24 
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type viruses (Heise, Hermiston et al. 2000; Bauerschmitz, Lam et al. 2002). Oncolysis caused 
by Delta2-Delta24 was approximately 10-fold less than with the other versions of E1. This is 
in concordance to other publications showing that viruses with multiple modifications feature 
slower rates of replication (Alemany, Balague et al. 2000; Balague, Noya et al. 2001). 
Interestingly, we saw little or no additional specificity when the Delta2 mutation was added to 
Delta24. Thus, the double modified E1A does not seem to provide specificity benefits over 
the single modified E1A (Delta24), but does reduce efficacy.  
The specificity of heterologous promoters can be affected by viral elements such as the 
inverted terminal repeats. Therefore, it is important to note that the specificity of the cox2 
promoter seemed retained: in the low cox2 expressing cell line BT474 the rates of replication 
were 100-fold lower than with wild type. In contrast, in the cox2 positive cell line A549, 
replication of the CRAds was similar to Ad5 wild type, except for the double modified 
Delta2-Delta24, which was slower. A549 cells express CAR to high degree (Wu, Fernandez et 
al. 2001) and therefore this cell line allows comparison of the CRAds to Ad5wt in a situation 
where all viruses infect cells effectively. 
Ovarian cancer cells have been reported refractory to infection with adenovirus. Therefore, we 
sought to transductionally target the novel CRAds by utilization of the serotype 3 knob. In 
OV-4 and SKOV3.ip1 cells Ad5wt resulted in little oncolysis, while the Ad5/3 CRAds were 
up to 1000-fold more effective in infecting and killing cells, due to higher expression of the 
serotype 3 receptor (Kanerva, Mikheeva et al. 2002). In Hey and ES-2 there was a ca. 10-fold 
difference in cell killing. The same was true for the fibroblast cell line FHS173WE, which 
displays little CAR but seems to express the adenovirus 3 receptor, because it allows viruses 
with the serotype 3 knob to enter cells. With incubation times similar to the cancer cell lines, 
no oncolysis was evident. However, when longer incubation times were used, killing was 
seen. To investigate this further, we are in the process of determining the cox2 expression of 
this fibroblast line, and if adenovirus infection can induce cox2 in these cells. Although it is 
difficult to interpret this with regard to potential toxicity, as most fibroblasts in vivo would not 
be dividing (as opposed to fibroblasts in vitro), we felt that this might be a stringent model for 
detecting potential differences with regard to specificity between the CRAds. 
Interestingly, all 5/3 CRAds seemed to replicate in FHS173WE cells, and the promoter 
increased the selectivity of the virus significantly compared to Ad5/3d24 (p<0.01 at 1 
VP/cell) with a 10-fold difference in cell killing.  
In addition, we demonstrated that the cox2 promoter driven CRAds killed tumor cells with 
comparative or even superior efficacy when compared to Ad5/3d24, which is the isogenic 
Delta24 virus with the serotype 3 knob. This is most likely due to a higher amount of E1A 
proteins produced, when expressed from the cox2 promoter. This could improve replication, 
or increase cell killing might be due to the anti-tumor effect of E1A proteins per se
(Hortobagyi, Ueno et al. 2001). In non-replicating fibroblasts replication of the cox2 driven 
CRAds was reduced and none of the tested viruses lysed human peripheral blood 
mononuclear cells (PBMC) which might be useful from a safety standpoint (Bauerschmitz, 
Kanerva et al. 2004).  
As the liver is an important organ with regard to toxicity from adenoviral gene therapy 
(Raper, Chirmule et al. 2003), we evaluated primary human hepatocytes (nHEPs) with regard 
to replication permissivity. None of our CRAds replicated in these cells, resulting in at least 
100-fold difference in replication compared to Ad5 wild type. These results suggest the 
potential for low liver toxicity. Nevertheless, in addition to hepatocytes, human livers contain 
other cell types such as endothelial cells and specialized macrophages known as Kupffer cells. 
Also, as the tertiary structure of the liver may also be important with regard to adenoviral 
gene transfer, more advanced models or clinical trials are needed to reliably evaluate toxicity. 
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In conclusion, our results suggest increased specificity and efficacy for viruses featuring the 
cox2 promoter with the Delta24 deletion, in comparison to viruses without the deletion. 
Further, CRAds with Delta24 seemed advantageous over viruses with Delta2-Delta24 due to 
stronger replication, while the specificity was similar. Further, cox2Delta24 was more 
oncolytic than cox2E1 or Ad5/3d24. When data from ovarian cancer cells (cox2-Delta24 100-
fold more effective) are combined to data from hepatocytes (Ad5wt 100 - 1000 fold more 
toxic), the cox2Delta24 configuration increased the therapeutic window by 10 000 – 100 000 
fold in comparison to Ad5wt. With regard to promoter configuration cox2L was more specific 
and effective than cox2M. Therefore, cox2L-Delta24 emerges as the agent of choice for 
further studies which may eventually facilitate clinical testing of the agent. 
9.  Therapeutic efficacy of triple-targeted selectively oncolytic adenoviruses in vivo (IV) 
The ultimate preclinical tests of experimental therapeutics are in vivo models. Ovarian cancer 
cell xenografts were established subcutaneously and injected with viruses. Ad5/3Cox2Ld24 
had more antitumor effect than the positive control Ad300wt (P=0.0001), and was more 
effective than negative controls Ad5LacZ (P<0.01) and mock (P<0.001), and had similar 
efficacy to Ad5/3d24 (P=0.4). In this aggressive model, Ad5/3Cox2Ld2d24 and 
Ad5/3Cox2LE1 were not more effective than negative controls (P not significant). 
To evaluate replication of the viruses in vivo, CRADs were coinfected with a luciferase 
expressing virus (Ad5/3Luc1), which replicates only in the presence of E1 produced by 
replication of the CRADs. In comparison to tumors coinfected with replication deficient virus 
(Ad5LacZ), tumors coinfected with CRADs demonstrated more luciferase expression (all 
P<0.01).
Finally, to mimic advanced stage ovarian cancer in an orthotopic animal model, SKOV3.ip1 
ovarian cancers were established intraperitoneally with 107 cells/mouse. Tumors were allowed 
to grow for 7 days and then mice were injected with 108 VP/day or mock for three 
consecutive days. After 90 days Ad300wt (P=0.002), Ad5/3Cox2Ld24 (P<0.001) and 
Ad5/3d24 (P<0.001) resulted in significant longer survival than mock. Ad5/3Cox2Ld24 
(P=0.120) and Ad5/3d24 (P=0.148) also displayed a trend for more antitumor effect than the 
positive control Ad300wt, but the differences were not statistically significant 
Ad5/3Cox2Ld24 had similar efficacy to Ad5/3d24 (P=0.971). Again, cox2L-Delta24 emerges 
as the agent of choice for further studies which may eventually facilitate clinical testing of the 
agent.
45
SUMMARY AND CONCLUSIONS 
In this thesis, the evolution of adenoviral therapy is described from its early beginnings with 
poorly characterized preparations of wild type viruses to non-replicative adenoviral vectors to 
most recent generation of multiple modified conditionally replicating adenoviruses. 
Any promoters that retain fidelity when placed in the Ad genome, achieve good levels of 
transgene expression and have a “liver off” phenotype are potentially interesting for clinical 
testing. We showed activity of the flt-1 promoter in teratocarcinoma cells derived from 
ovarian or testicular tissue. The close correlation of transgene expression and flt-1 mRNA 
seen is further evidence that this promoter may have the required characteristics. The data, 
obtained in the current study, suggest that flt-1 could be useful for transcriptionally targeting 
teratocarcinoma. 
Further, we have then utilized a replication competent agent, Ad5- 24RGD, in ovarian cancer 
models. We observed replication and oncolytic potency similar to a wild type control virus for 
ovarian cancer cell lines and in a three dimensional spheroid model. We detected an 
exponential increase in the amount of Ad5- 24RGD gene copies suggesting efficient 
replication. Finally, in an orthotopic murine model of peritoneally metastatic ovarian cancer 
we saw significant improvement in survival of the animals with complete eradication of ip. 
disease. Thus, Ad5- 24RGD could be an effective agent for treatment of ovarian cancer, and 
because Rb/p16 pathway defects are ubiquitous in human cancers, we sought to extend these 
studies to cervical cancer. Ad5- 24RGD was administered locally and systemically. 
Therapeutic efficacy was seen with amounts of virus (converted into human doses) that seem 
amenable to clinical testing, and have been safe in trials with other CRADs. These results 
suggest that Ad5- 24RGD may be a useful agent for testing in clinical trials with ovarian or 
cervical cancer patients suffering from disease refractory to current treatment modalities. 
Although the safety of Ads has been good in human trial heretofore, the emergence of more 
effective, tropism modified and replication competent agents suggests that improving 
specificity might be useful. We utilized two variants of the cox2 promoter in combination 
with E1-transcomplementation and found increased specificity and efficacy for viruses 
featuring the cox2 promoter with the Delta24 deletion, in comparison to viruses without the 
deletion. Further, CRAds with Delta24 seemed advantageous over viruses with Delta2-
Delta24 due to stronger replication, while the specificity was similar. Impressively, 
cox2Delta24 was similar or even more oncolytic than cox2E1 or Ad5/3d24. When data from 
ovarian cancer cells (cox2-Delta24 100-fold more effective) are combined to data from 
hepatocytes (Ad5wt 100 - 1000 fold more toxic), the cox2Delta24 configuration increased the 
therapeutic window by 10 000 – 100 000 fold in comparison to Ad5wt. With regard to 
promoter configuration cox2L was more specific and effective than cox2M. Therefore, 
cox2L-Delta24 emerges as the agent of choice for further studies which may eventually 
facilitate clinical testing of the agent.  
In conclusion, effective but specific tumor transduction continue to be the limiting steps for 
adenoviral vectors, and advanced generation replicating agents like CRAds are emerging as 
promising agents for overcoming some of the obstacles. One central problem has been that the 
primary receptor, CAR, is often expressed at variable levels on primary tumor tissue whereas 
in normal tissue and especially the liver its levels are high. Thus, targeting strategies and 
infectivity enhancements methods have been developed and promising preclinical data sets 
the stage for clinical testing. Though other viral vectors might be more useful for treatment of 
hereditary and acquired diseases, adenoviruses are highly promising and safe agents for 
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oncology, as suggested in number of clinical trials. Importantly, synergism and a lack of cross 
resistance of CRAds with chemotherapy or radiation therapy has been demonstrated. Thus, 
combination treatments seem lucrative for testing in trials. 
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